Pyrimido[4,5-b]quinoline-4,5(3H,10H)-diones

ABSTRACT

The invention relates to compound of the formula (I); or a salt thereof, wherein the substituents are as defined in the specification; to its preparation, to its use as medicament and to medicaments comprising it.

The invention relates to pyrimido[4,5-b]quinoline-4,5(3H,10H)-diones, totheir preparation, to their use as medicaments and to medicamentscomprising them.

Many human genetic diseases are caused by nonsense mutations (seeKeeling et al, WIREs RNA, 2011, 2, 837-852; Linde et al, Trends inGenetics, 2008, 24(11), 552-563; and Rose et al, Pharmacology &Therapeutics, 2012 136(2), 227-266).

A nonsense mutation is a genetic mutation leading to the transformationof a sense codon into a premature termination codon (hereinafter PTC)upstream from the normal termination codon.

Eukaryotic termination codons are UAA, UAG or UGA.

The normal termination codon stops gene translation and enablesfull-length, wild type protein synthesis. A PTC prevents such wild typeprotein synthesis and leads to truncated, in many cases inactive,proteins. The resulting partial/total lack of protein leads to thepathology of the disease caused by such a nonsense mutation.

Nonsense mutations can be in-frame mutations, e.g. single nucleic acidexchanges transforming a single codon into a PTC, or frameshiftmutations, e.g. a single nucleic acid insertion/deletion transformingthe affected codon into a PTC.

A compound being able to suppress the effect of a nonsense mutation isherein called a “nonsense mutation suppressor”.

One mechanism to suppress the effect of nonsense mutations is toincrease the rate of readthrough events during translation. A compoundhaving this mechanism of action is herein called a “readthroughactivator”. In a readthrough event, an aminoacyl tRNA being near-cognateis used to recode a termination codon into a sense codon. Under basalconditions, the recoding of a PTC into a sense codon occurs in less than1% of translation events, while suppression of a normal stop codonoccurs at a frequency of <0.1%. Amino acids inserted by recoding willnot necessarily be identical to the corresponding amino acids of thewild-type protein; however many amino acid substitutions arefunctionally tolerated. Thus, a protein produced by readthroughactivation may possess activity strongly similar to the wild-typeprotein. Consequently, by increasing the rate of PTC-recoding enoughfunctional protein may be restored to provide a therapeutic benefit topatients carrying a nonsense mutation.

Another mechanism to suppress the effect of nonsense mutations is toinhibit nonsense-mediated mRNA decay (NMD). A compound having thismechanism of action is herein called a “NMD inhibitor”. NMD regulatesthe total level of PTC-bearing transcripts: it detects and degrades suchtranscripts to prevent synthesis of truncated proteins which might benonfunctional or deleterious owing to dominant-negative orgain-of-function effects. Inhibition of NMD increases the number oftranscripts available which could also be a mechanism to restore enoughfunctional protein for a therapeutic benefit.

Compounds described as nonsense mutation suppressors are certainaminoglycoside antibiotics, e.g. in WO2007113841, and certain1,2,4-oxadiazole benzoic acids, e.g. in WO2004091502.

The following pyrimido[4,5-b]quinoline-4,5(3H,10H)-diones have beenpublished in catalogues of suppliers of chemical compounds withoutindicating usefulness of compounds:

Ex Structure Name CAS number 1.28

2-isopropyl-10-methyl- 3-phenylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione 883958-40-5 1.29

10-methyl-2-pentyl-3- phenylpyrimido[4,5- b]quinoline-4,5(3H,10H)-dione898913-20-7 1.30

10-methyl-3-phenyl-2- propylpyrimido[4,5-b]quinoline- 4,5(3H,10H)-dione898923-07-4 1.31

2-ethyl-10-methyl-3- phenylpyrimido[4,5-b]quinoline- 4,5(3H,10H)-dione883958-38-1 1.33

3-(3,5-dimethylphenyl)-2-ethyl- 10-methylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione 898921-75-0 1.34

3-(3,5-dimethylphenyl)-10- methyl-2-pentylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione 896597-46-9 1.35

3-(3,5-dimethylphenyl)-2-isopropyl- 10-methylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione 883960-31-4 1.36

3-(3,5-dimethylphenyl)-10-methyl- 2-propylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione 899404-28-5 2.15

3-cyclopentyl-2-isopropyl-10- methylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione 898918-28-0 2.18

3-cyclopentyl-10-methyl-2- pentylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione 883961-07-7 2.21

3-cyclopentyl-10-methyl-2- propylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione 883961-12-4 2.24

3-cyclohexyl-10-methyl-2- propylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione 898912-80-6 2.29

3-cyclohexyl-2-isopropyl-10- methylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione 879773-75-8

3-cyclopentyl-2-ethyl-10- methylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione 898916-50-2

Nonsense mutation suppressors are considered to be useful in thetreatment of a wide range of diseases caused by nonsense mutations.Prominent examples of diseases caused by nonsense mutations are diseasescaused by nonsense mutations in lysosomal enzymes, e.g.mucopolysaccharidosis I (Hurler syndrome) caused by nonsense mutationsin α-L-iduronidase; hemophilia A or hemophilia B caused by nonsensemutations in coagulation factors 7, 8 or 9; cystic fibrosis caused bynonsense mutations in the chloride channel CFTR; diseases caused bynonsense mutations in structural proteins, e.g. Duchenne or BeckerMuscle Dystrophy caused by nonsense mutations in dystrophin; or cancercaused by nonsense mutations in APC or p53.

There is a need to provide new nonsense mutation suppressors that aregood drug candidates. In particular, preferred compounds should bepotent nonsense mutation suppressors whilst showing little potency inother drug target assays, e.g. GPCR or ion channel assays. They shouldexhibit a low binding to plasma proteins. They should be well absorbedfrom the gastrointestinal tract, be sufficiently metabolically stableand possess favorable pharmacokinetic properties. They should benon-toxic and demonstrate few side-effects. Furthermore, the ideal drugcandidate will be able to exist in a physical form that is stable,non-hygroscopic and easily formulated.

The compounds of the invention are nonsense mutation suppressors and aretherefore potentially useful in the treatment of a wide range ofdiseases caused by nonsense mutations, particularly wherein the diseaseis selected from hemophilia A, hemophilia B, cystic fibrosis,mucopolysaccharidosis I, Duchenne Muscle Dystrophy, Becker MuscleDystrophy, loss of APC caused cancer and loss of p53 caused cancer.

In a first aspect, the invention relates to a compound of formula (I)

or a salt thereof, wherein

R₁ is a five- to seven-membered monocyclic saturated or unsaturatednon-aromatic ring system, wherein said ring system may contain from 1 to4 hetero atoms selected from nitrogen, oxygen and sulfur, and whereinsaid ring system may be substituted once or more than once by R₆;

and

R₂ is C₂₋₆alkyl which may be substituted once or more than once by R₇;

or R₂ is —X₁—R₈; —X₁— is —O—, —S— or —N(R₉)—; R₉ is hydrogen orC₁₋₄alkyl; and R₈ is C₁₋₆alkyl which may be substituted once or morethan once by R₁₀;or R₂ is a three- to seven-membered monocyclic aromatic, saturated orunsaturated non-aromatic ring system, wherein said ring system maycontain from 1 to 4 hetero atoms selected from nitrogen, oxygen andsulfur, and wherein said ring system may be substituted once or morethan once by R₁₁;or

R₁ is

wherein the phenyl ring is attached via the bond marked with anasterisk;each R₁₂ independently is hydrogen, halogen, hydroxyl, amino, cyano,nitro, C₁₋₄alkyl, C₁₋₄ halogenalkyl, C₁₋₄hydroxyalkyl,C₁₋₄alkoxy-C₁₋₄alkyl, amino-C₁₋₄alkyl, C₁₋₄alkyl-amino-C₁₋₄alkyl,di(C₁₋₄alkyl)-amino-C₁₋₄alkyl, C₁₋₄alkoxy, C₁₋₄halogenalkoxy,C₁₋₄alkylamino or di(C₁₋₄ alkyl)amino; or C₃₋₆cycloalkyl, wherein onecarbon atom may be replaced by an oxygen atom, wherein theC₃₋₆cycloalkyl may be attached directly or via a C₁₋₂alkylene, andwherein the C₃₋₆cycloalkyl may be substituted once or more than once byhalogen;and

R₂ is C₂₋₇alkyl which may be substituted once or more than once by R₁₃;

or R₂ is —X₂—R₁₄; —X₂— is —O—, —S— or —N(R₁₅)—; R₁₅ is hydrogen orC₁₋₄alkyl; and R₁₄ is C₁₋₆alkyl which may be substituted once or morethan once by R₁₆;or R₂ is a three- to seven-membered monocyclic saturated or unsaturatednon-aromatic ring system, wherein said ring system may contain from 1 to4 hetero atoms selected from nitrogen, oxygen and sulfur, and whereinsaid ring system may be substituted once or more than once by R₁₇;

R₃ is hydrogen or —CH₂R₁₈;

R₁₈ is hydrogen, C₁₋₄alkyl, C₂₋₆alkenyl, C₃₋₆cycloalkyl,C₁₋₃alkoxyC₁₋₃alkyl, hydroxyC₁₋₃alkyl, or aminoC₁₋₃alkyl;

and

R₄ is hydrogen, halogen, hydroxyl, amino, cyano, C₁₋₄alkyl,C₁₋₄halogenalkyl, C₁₋₄ hydroxyalkyl, C₁₋₄alkoxy-C₁₋₄alkyl,amino-C₁₋₄alkyl, C₁₋₄alkyl-amino-C₁₋₄alkyl,di(C₁₋₄alkyl)-amino-C₁₋₄alkyl, C₁₋₄alkoxy, C₁₋₄halogenalkoxy,C₁₋₄alkylamino or di(C₁₋₄alkyl)amino;

or a three- to seven-membered monocyclic aromatic, saturated orunsaturated non-aromatic ring system, wherein said ring system maycontain from 1 to 4 hetero atoms selected from nitrogen, oxygen andsulfur, wherein said ring system may be attached directly or via aC₁₋₂alkylene, and wherein said ring system may be substituted once ormore than once by R₁₉;or

R₃ and R₄ taken together are —CH₂—CH₂—;

R₅ is hydrogen, halogen, hydroxyl, cyano, C₁₋₄alkyl, C₁₋₄halogenalkyl,C₁₋₄hydroxyalkyl, C₁₋₄ alkoxy-C₁₋₄alkyl, amino-C₁₋₄alkyl,C₁₋₄alkyl-amino-C₁₋₄alkyl, di(C₁₋₄alkyl)-amino-C₁₋₄alkyl, C₂₋₄alkenyl,C₂₋₄alkinyl, C₁₋₄alkoxy or C₁₋₄halogenalkoxy; or C₃₋₄cycloalkyl, whereinone carbon atom may be replaced by an oxygen atom, wherein theC₃₋₄cycloalkyl may be attached directly or via a C₁₋₂alkylene, andwherein the C₃₋₄cycloalkyl may be substituted once or more than once byhalogen;

R₆, R₁₁, R₁₇ and R₁₉ each independently is halogen, hydroxyl, amino,cyano, nitro, C₁₋₄alkyl, C₁₋₄halogenalkyl, C₁₋₄hydroxyalkyl,C₁₋₄alkoxy-C₁₋₄alkyl, amino-C₁₋₄alkyl, C₁₋₄alkyl-amino-C₁₋₄alkyl,di(C₁₋₄alkyl)-amino-C₁₋₄alkyl, C₁₋₄alkoxy, C₁₋₄halogenalkoxy,C₁₋₄alkylamino or di(C₁₋₄ alkyl)amino;

or C₃₋₆cycloalkyl, wherein one carbon atom may be replaced by an oxygenatom, wherein the C₃₋₆cycloalkyl may be attached directly or via aC₁₋₂alkylene, and wherein the C₃₋₆cycloalkyl may be substituted once ormore than once by halogen;or two R₆, R₁₁, R₁₇ or R₁₉ at the same ring atom together are oxo;or two R₆, R₁₁, R₁₇ or R₁₉ at the same ring carbon atom together withsaid carbon atom form a C₃₋₆cycloalkyl;

R₇, R₁₀, R₁₃ and R₁₆ each independently is halogen, hydroxyl, amino,cyano, nitro, C₁₋₄alkoxy, C₁₋₄halogenalkoxy, C₁₋₄alkylamino ordi(C₁₋₄alkyl)amino;

or C₃₋₆cycloalkyl, wherein one carbon atom may be replaced by an oxygenatom, wherein the C₃₋₆cycloalkyl may be attached directly or via aC₁₋₂alkylene, and wherein the C₃₋₆cycloalkyl may be substituted once ormore than once by halogen;or two R₇, R₁₀, R₁₃ or R₁₆ at the same carbon atom together are oxo;or two R₇, R₁₀, R₁₃ or R₁₆ at the same carbon atom together with saidcarbon atom form a C₃₋₆ cycloalkyl;for use as a medicament for the treatment of a disease caused by anonsense mutation.

In a second aspect, the invention relates to a compound of formula (I)

or a salt thereof, wherein

R₁ is a five- to six-membered monocyclic saturated or unsaturatednon-aromatic ring system, wherein said ring system may contain from 1 to4 hetero atoms selected from nitrogen, oxygen and sulfur, and whereinsaid ring system may be substituted once or more than once by R₆;

and

R₂ is C₂₋₆alkyl which may be substituted once or more than once by R₇;

or R₂ is —X₁—R₈; —X₁— is —O—, —S— or —N(R₉)—; R₉ is hydrogen orC₁₋₄alkyl; and R₈ is C₁₋₆alkyl which may be substituted once or morethan once by R₁₀;or R₂ is a three- to five-membered monocyclic saturated or unsaturatednon-aromatic ring system, wherein said ring system may contain from 1 to4 hetero atoms selected from nitrogen, oxygen and sulfur, and whereinsaid ring system may be substituted once or more than once by R₁₁;or

R₁ is

wherein the phenyl ring is attached via the bond marked with anasterisk;each R₁₂ independently is hydrogen, halogen, hydroxyl, amino, cyano,nitro, C₁₋₄alkyl, C₁₋₄ halogenalkyl, C₁₋₄hydroxyalkyl,C₁₋₄alkoxy-C₁₋₄alkyl, amino-C₁₋₄alkyl, C₁₋₄alkyl-amino-C₁₋₄alkyl,di(C₁₋₄alkyl)-amino-C₁₋₄alkyl, C₁₋₄alkoxy, C₁₋₄halogenalkoxy,C₁₋₄alkylamino or di(C₁₋₄ alkyl)amino; or C₃₋₆cycloalkyl, wherein onecarbon atom may be replaced by an oxygen atom, wherein theC₃₋₆cycloalkyl may be attached directly or via a C₁₋₂alkylene, andwherein the C₃₋₆cycloalkyl may be substituted once or more than once byhalogen;and

R₂ is C₂₋₇alkyl which may be substituted once or more than once by R₁₃;

or R₂ is —X₂—R₁₄; —X₂— is —O—, —S— or —N(R₁₅)—; R₁₅ is hydrogen orC₁₋₄alkyl; and R₁₄ is C₁₋₆alkyl which may be substituted once or morethan once by R₁₆;or R₂ is a three- to five-membered monocyclic saturated or unsaturatednon-aromatic ring system, wherein said ring system may contain from 1 to4 hetero atoms selected from nitrogen, oxygen and sulfur, and whereinsaid ring system may be substituted once or more than once by R₁₇;

R₃ is hydrogen or —CH₂R₁₈;

R₁₈ is hydrogen, C₁₋₄alkyl, C₂₋₆alkenyl, C₃₋₆cycloalkyl,C₁₋₃alkoxyC₁₋₃alkyl, hydroxyC₁₋₃alkyl, or aminoC₁₋₃alkyl;

and

R₄ is hydrogen, halogen, hydroxyl, amino, cyano, C₁₋₄alkyl,C₁₋₄halogenalkyl, C₁₋₄hydroxyalkyl, C₁₋₄alkoxy-C₁₋₄alkyl,amino-C₁₋₄alkyl, C₁₋₄alkyl-amino-C₁₋₄alkyl,di(C₁₋₄alkyl)-amino-C₁₋₄alkyl, C₁₋₄alkoxy, C₁₋₄halogenalkoxy,C₁₋₄alkylamino or di(C₁₋₄alkyl)amino;

or a three- to seven-membered monocyclic aromatic, saturated orunsaturated non-aromatic ring system, wherein said ring system maycontain from 1 to 4 hetero atoms selected from nitrogen, oxygen andsulfur, wherein said ring system may be attached directly or via aC₁₋₂alkylene, and wherein said ring system may be substituted once ormore than once by R₁₉;or

R₃ and R₄ taken together are —CH₂—CH₂—;

R₅ is hydrogen, halogen, hydroxyl, cyano, C₁₋₄alkyl, C₂₋₄alkenyl,C₂₋₄alkinyl or C₁₋₄alkoxy; or C₃₋₄cycloalkyl, wherein one carbon atommay be replaced by an oxygen atom, wherein the C₃₋₄cycloalkyl may beattached directly or via a C₁₋₂alkylene;

R₆, R₁₁, R₁₇ and R₁₉ each independently is halogen, hydroxyl, amino,cyano, nitro, C₁₋₄alkyl, C₁₋₄halogenalkyl, C₁₋₄hydroxyalkyl,C₁₋₄alkoxy-C₁₋₄alkyl, amino-C₁₋₄alkyl, C₁₋₄alkyl-amino-C₁₋₄alkyl,di(C₁₋₄alkyl)-amino-C₁₋₄alkyl, C₁₋₄alkoxy, C₁₋₄halogenalkoxy,C₁₋₄alkylamino or di(C₁₋₄ alkyl)amino;

or C₃₋₆cycloalkyl, wherein one carbon atom may be replaced by an oxygenatom, wherein the C₃₋₆cycloalkyl may be attached directly or via aC₁₋₂alkylene, and wherein the C₃₋₆cycloalkyl may be substituted once ormore than once by halogen;or two R₆, R₁₁, R₁₇ or R₁₉ at the same ring atom together are oxo;or two R₆, R₁₁, R₁₇ or R₁₉ at the same ring carbon atom together withsaid carbon atom form a C₃₋₆cycloalkyl;

R₇, R₁₀, R₁₃ and R₁₆ each independently is halogen, hydroxyl, amino,cyano, nitro, C₁₋₄alkoxy, C₁₋₄halogenalkoxy, C₁₋₄alkylamino ordi(C₁₋₄alkyl)amino;

or C₃₋₆cycloalkyl, wherein one carbon atom may be replaced by an oxygenatom, wherein the C₃₋₆cycloalkyl may be attached directly or via aC₁₋₂alkylene, and wherein the C₃₋₆cycloalkyl may be substituted once ormore than once by halogen;or two R₇, R₁₀, R₁₃ or R₁₆ at the same carbon atom together are oxo;or two R₇, R₁₀, R₁₃ or R₁₆ at the same carbon atom together with saidcarbon atom form a C₃₋₆ cycloalkyl;for use as a medicament.

In a third aspect, the invention relates to a compound of formula (I)

or a salt thereof, wherein

R₁ is a five- to six-membered monocyclic saturated or unsaturatednon-aromatic ring system, wherein said ring system may contain from 1 to4 hetero atoms selected from nitrogen, oxygen and sulfur, and whereinsaid ring system may be substituted once or more than once by R₆;

and

R₂ is C₂₋₆alkyl which may be substituted once or more than once by R₇;

or R₂ is —X₁—R₈; —X₁— is —O—, —S— or —N(R₉)—; R₉ is hydrogen orC₁₋₄alkyl; and R₈ is C₁₋₆alkyl which may be substituted once or morethan once by R₁₀;or R₂ is a three- to five-membered monocyclic saturated or unsaturatednon-aromatic ring system, wherein said ring system may contain from 1 to4 hetero atoms selected from nitrogen, oxygen and sulfur, and whereinsaid ring system may be substituted once or more than once by R₁₁;or

R₁ is

wherein the phenyl ring is attached via the bond marked with anasterisk;each R₁₂ independently is hydrogen, halogen, hydroxyl, amino, cyano,nitro, C₁₋₄alkyl, C₁₋₄halogenalkyl, C₁₋₄hydroxyalkyl,C₁₋₄alkoxy-C₁₋₄alkyl, amino-C₁₋₄alkyl, C₁₋₄alkyl-amino-C₁₋₄alkyl,di(C₁₋₄alkyl)-amino-C₁₋₄alkyl, C₁₋₄alkoxy, C₁₋₄halogenalkoxy,C₁₋₄alkylamino or di(C₁₋₄ alkyl)amino; or C₃₋₆cycloalkyl, wherein onecarbon atom may be replaced by an oxygen atom, wherein theC₃₋₆cycloalkyl may be attached directly or via a C₁₋₂alkylene, andwherein the C₃₋₆cycloalkyl may be substituted once or more than once byhalogen;and

R₂ is C₂₋₇alkyl which may be substituted once or more than once by R₁₃;

or R₂ is —X₂—R₁₄; —X₂— is —O—, —S— or —N(R₁₅)—; R₁₅ is hydrogen orC₁₋₄alkyl; and R₁₄ is C₁₋₆alkyl which may be substituted once or morethan once by R₁₆;or R₂ is a three- to five-membered monocyclic saturated or unsaturatednon-aromatic ring system, wherein said ring system may contain from 1 to4 hetero atoms selected from nitrogen, oxygen and sulfur, and whereinsaid ring system may be substituted once or more than once by R₁₇;

R₃ is hydrogen or —CH₂R₁₈;

R₁₈ is hydrogen, C₁₋₄alkyl, C₂₋₆alkenyl, C₃₋₆cycloalkyl,C₁₋₃alkoxyC₁₋₃alkyl, hydroxyC₁₋₃alkyl, or aminoC₁₋₃alkyl;

and

R₄ is hydrogen, halogen, hydroxyl, amino, cyano, C₁₋₄alkyl,C₁₋₄halogenalkyl, C₁₋₄ hydroxyalkyl, C₁₋₄alkoxy-C₁₋₄alkyl,amino-C₁₋₄alkyl, C₁₋₄alkyl-amino-C₁₋₄alkyl,di(C₁₋₄alkyl)-amino-C₁₋₄alkyl, C₁₋₄alkoxy, C₁₋₄halogenalkoxy,C₁₋₄alkylamino or di(C₁₋₄alkyl)amino;

or a three- to seven-membered monocyclic aromatic, saturated orunsaturated non-aromatic ring system, wherein said ring system maycontain from 1 to 4 hetero atoms selected from nitrogen, oxygen andsulfur, wherein said ring system may be attached directly or via a C₁₋₂alkylene, and wherein said ring system may be substituted once or morethan once by R₁₉; or

R₃ and R₄ taken together are —CH₂—CH₂—;

R₅ is hydrogen, halogen, hydroxyl, cyano, C₁₋₄alkyl, C₂₋₄alkenyl,C₂₋₄alkinyl or C₁₋₄alkoxy; or C₃₋₄cycloalkyl, wherein one carbon atommay be replaced by an oxygen atom, wherein the C₃₋₄cycloalkyl may beattached directly or via a C₁₋₂alkylene;

R₆, R₁₁, R₁₇ and R₁₉ each independently is halogen, hydroxyl, amino,cyano, nitro, C₁₋₄alkyl, C₁₋₄halogenalkyl, C₁₋₄hydroxyalkyl,C₁₋₄alkoxy-C₁₋₄alkyl, amino-C₁₋₄alkyl, C₁₋₄alkyl-amino-C₁₋₄alkyl,di(C₁₋₄alkyl)-amino-C₁₋₄alkyl, C₁₋₄alkoxy, C₁₋₄halogenalkoxy,C₁₋₄alkylamino or di(C₁₋₄ alkyl)amino;

or C₃₋₆cycloalkyl, wherein one carbon atom may be replaced by an oxygenatom, wherein the C₃₋₆cycloalkyl may be attached directly or via aC₁₋₂alkylene, and wherein the C₃₋₆cycloalkyl may be substituted once ormore than once by halogen;or two R₆, R₁₁, R₁₇ or R₁₉ at the same ring atom together are oxo;or two R₆, R₁₁, R₁₇ or R₁₉ at the same ring carbon atom together withsaid carbon atom form a C₃₋₆cycloalkyl;

R₇, R₁₀, R₁₃ and R₁₆ each independently is halogen, hydroxyl, amino,cyano, nitro, C₁₋₄alkoxy, C₁₋₄halogenalkoxy, C₁₋₄alkylamino ordi(C₁₋₄alkyl)amino;

or C₃₋₆cycloalkyl, wherein one carbon atom may be replaced by an oxygenatom, wherein the C₃₋₆cycloalkyl may be attached directly or via aC₁₋₂alkylene, and wherein the C₃₋₆cycloalkyl may be substituted once ormore than once by halogen;or two R₇, R₁₀, R₁₃ or R₁₆ at the same carbon atom together are oxo;or two R₇, R₁₀, R₁₃ or R₁₆ at the same carbon atom together with saidcarbon atom form a C₃₋₆ cycloalkyl;provided the compound is not

-   2-isopropyl-10-methyl-3-phenylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione;-   10-methyl-2-pentyl-3-phenylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione;-   10-methyl-3-phenyl-2-propylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione;-   2-ethyl-10-methyl-3-phenylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione;-   3-(3,5-dimethylphenyl)-2-ethyl-10-methylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione;-   3-(3,5-dimethylphenyl)-10-methyl-2-pentylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione;-   3-(3,5-dimethylphenyl)-2-isopropyl-10-methylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione;-   3-(3,5-dimethylphenyl)-10-methyl-2-propylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione;-   3-cyclopentyl-2-isopropyl-10-methylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione;-   3-cyclopentyl-10-methyl-2-pentylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione;-   3-cyclopentyl-10-methyl-2-propylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione;-   3-cyclohexyl-10-methyl-2-propylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione;-   3-cyclohexyl-2-isopropyl-10-methylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione;    or-   3-cyclopentyl-2-ethyl-10-methylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione.

In a fourth aspect, the invention relates to a compound of formula (I)

or a salt thereof, wherein

R₁ is a five- to seven-membered monocyclic saturated or unsaturatednon-aromatic ring system, wherein said ring system may contain from 1 to4 hetero atoms selected from nitrogen, oxygen and sulfur, and whereinsaid ring system may be substituted once or more than once by R₆;

and

R₂ is C₂₋₆alkyl which may be substituted once or more than once by R₇;

or R₂ is —X₁—R₈; —X₁— is —O—, —S— or —N(R₉)—; R₉ is hydrogen orC₁₋₄alkyl; and R₈ is C₁₋₆alkyl which may be substituted once or morethan once by R₁₀;or R₂ is a three- to seven-membered monocyclic aromatic, saturated orunsaturated non-aromatic ring system, wherein said ring system maycontain from 1 to 4 hetero atoms selected from nitrogen, oxygen andsulfur, and wherein said ring system may be substituted once or morethan once by R₁₁;or

R₁ is

wherein the phenyl ring is attached via the bond marked with anasterisk;each R₁₂ independently is hydrogen, halogen, hydroxyl, amino, cyano,nitro, C₁₋₄alkyl, C₁₋₄ halogenalkyl, C₁₋₄hydroxyalkyl,C₁₋₄alkoxy-C₁₋₄alkyl, amino-C₁₋₄alkyl, C₁₋₄alkyl-amino-C₁₋₄alkyl,di(C₁₋₄alkyl)-amino-C₁₋₄alkyl, C₁₋₄alkoxy, C₁₋₄halogenalkoxy,C₁₋₄alkylamino or di(C₁₋₄ alkyl)amino; or C₃₋₆cycloalkyl, wherein onecarbon atom may be replaced by an oxygen atom, wherein theC₃₋₆cycloalkyl may be attached directly or via a C₁₋₂alkylene, andwherein the C₃₋₆cycloalkyl may be substituted once or more than once byhalogen;and

R₂ is C₂₋₆alkyl which may be substituted once or more than once by R₁₃;

or R₂ is —X₂—R₁₄; —X₂— is —O—, —S— or —N(R₁₅)—; R₁₅ is hydrogen orC₁₋₄alkyl; and R₁₄ is C₁₋₆alkyl which may be substituted once or morethan once by R₁₆;or R₂ is a three- to seven-membered monocyclic saturated or unsaturatednon-aromatic ring system, wherein said ring system may contain from 1 to4 hetero atoms selected from nitrogen, oxygen and sulfur, and whereinsaid ring system may be substituted once or more than once by R₁₇;

R₃ is hydrogen or —CH₂R₁₈;

R₁₈ is hydrogen, C₁₋₄alkyl, C₂₋₆alkenyl or C₃₋₆cycloalkyl;

and

R₄ is hydrogen, halogen, hydroxyl, amino, cyano, C₁₋₄alkyl,C₁₋₄halogenalkyl, C₁₋₄hydroxyalkyl, C₁₋₄alkoxy-C₁₋₄alkyl,amino-C₁₋₄alkyl, C₁₋₄alkyl-amino-C₁₋₄alkyl,di(C₁₋₄alkyl)-amino-C₁₋₄alkyl, C₁₋₄alkoxy, C₁₋₄halogenalkoxy,C₁₋₄alkylamino or di(C₁₋₄alkyl)amino;

or a three- to seven-membered monocyclic aromatic, saturated orunsaturated non-aromatic ring system, wherein said ring system maycontain from 1 to 4 hetero atoms selected from nitrogen, oxygen andsulfur, wherein said ring system may be attached directly or via aC₁₋₂alkylene, and wherein said ring system may be substituted once ormore than once by R₁₉; or

R₃ and R₄ taken together are —CH₂—CH₂—;

R₅ is hydrogen, halogen, hydroxyl, cyano, C₁₋₄alkyl, C₁₋₄halogenalkyl,C₁₋₄hydroxyalkyl, C₁₋₄alkoxy-C₁₋₄alkyl, amino-C₁₋₄alkyl,C₁₋₄alkyl-amino-C₁₋₄alkyl, di(C₁₋₄alkyl)-amino-C₁₋₄alkyl, C₂₋₄alkenyl,C₂₋₄alkinyl, C₁₋₄alkoxy or C₁₋₄halogenalkoxy; or C₃₋₄cycloalkyl, whereinone carbon atom may be replaced by an oxygen atom, wherein theC₃₋₄cycloalkyl may be attached directly or via a C₁₋₂alkylene, andwherein the C₃₋₄cycloalkyl may be substituted once or more than once byhalogen;

R₆, R₁₁, R₁₇ and R₁₉ each independently is halogen, hydroxyl, amino,cyano, nitro, C₁₋₄alkyl, C₁₋₄halogenalkyl, C₁₋₄hydroxyalkyl,C₁₋₄alkoxy-C₁₋₄alkyl, amino-C₁₋₄alkyl, C₁₋₄alkyl-amino-C₁₋₄alkyl,di(C₁₋₄alkyl)-amino-C₁₋₄alkyl, C₁₋₄alkoxy, C₁₋₄halogenalkoxy,C₁₋₄alkylamino or di(C₁₋₄ alkyl)amino;

or C₃₋₆cycloalkyl, wherein one carbon atom may be replaced by an oxygenatom, wherein the C₃₋₆cycloalkyl may be attached directly or via aC₁₋₂alkylene, and wherein the C₃₋₆cycloalkyl may be substituted once ormore than once by halogen;or two R₆, R₁₁, R₁₇ or R₁₉ at the same ring atom together are oxo;or two R₆, R₁₁, R₁₇ or R₁₉ at the same ring carbon atom together withsaid carbon atom form a C₃₋₆cycloalkyl;

R₇, R₁₀, R₁₃ and R₁₆ each independently is halogen, hydroxyl, amino,cyano, nitro, C₁₋₄alkoxy, C₁₋₄halogenalkoxy, C₁₋₄alkylamino ordi(C₁₋₄alkyl)amino;

or C₃₋₆cycloalkyl, wherein one carbon atom may be replaced by an oxygenatom, wherein the C₃₋₆cycloalkyl may be attached directly or via aC₁₋₂alkylene, and wherein the C₃₋₆cycloalkyl may be substituted once ormore than once by halogen;or two R₇, R₁₀, R₁₃ or R₁₆ at the same carbon atom together are oxo;or two R₇, R₁₀, R₁₃ or R₁₆ at the same carbon atom together with saidcarbon atom form a C₃₋₆ cycloalkyl;for use as a medicament for the treatment of a disease caused by anonsense mutation.

In a fifth aspect, the invention relates to a compound of formula (I)

or a salt thereof, wherein

R₁ is a five- to six-membered monocyclic saturated or unsaturatednon-aromatic ring system, wherein said ring system may contain from 1 to4 hetero atoms selected from nitrogen, oxygen and sulfur, and whereinsaid ring system may be substituted once or more than once by R₆;

and

R₂ is C₂₋₆alkyl which may be substituted once or more than once by R₇;

or R₂ is —X₁—R₈; —X₁— is —O—, —S— or —N(R₉)—; R₉ is hydrogen orC₁₋₄alkyl; and R₈ is C₁₋₆alkyl which may be substituted once or morethan once by R₁₀;or R₂ is a three- to five-membered monocyclic saturated or unsaturatednon-aromatic ring system, wherein said ring system may contain from 1 to4 hetero atoms selected from nitrogen, oxygen and sulfur, and whereinsaid ring system may be substituted once or more than once by R₁₁;or

R₁ is

wherein the phenyl ring is attached via the bond marked with anasterisk;each R₁₂ independently is hydrogen, halogen, hydroxyl, amino, cyano,nitro, C₁₋₄alkyl, C₁₋₄halogenalkyl, C₁₋₄hydroxyalkyl,C₁₋₄alkoxy-C₁₋₄alkyl, amino-C₁₋₄alkyl, C₁₋₄alkyl-amino-C₁₋₄alkyl,di(C₁₋₄alkyl)-amino-C₁₋₄alkyl, C₁₋₄alkoxy, C₁₋₄halogenalkoxy,C₁₋₄alkylamino or di(C₁₋₄ alkyl)amino; or C₃₋₆cycloalkyl, wherein onecarbon atom may be replaced by an oxygen atom, wherein theC₃₋₆cycloalkyl may be attached directly or via a C₁₋₂alkylene, andwherein the C₃₋₆cycloalkyl may be substituted once or more than once byhalogen;and

R₂ is C₂₋₆alkyl which may be substituted once or more than once by R₁₃;

or R₂ is —X₂—R₁₄; —X₂— is —O—, —S— or —N(R₁₅)—; R₁₅ is hydrogen orC₁₋₄alkyl; and R₁₄ is C₁₋₆alkyl which may be substituted once or morethan once by R₁₆;or R₂ is a three- to five-membered monocyclic saturated or unsaturatednon-aromatic ring system, wherein said ring system may contain from 1 to4 hetero atoms selected from nitrogen, oxygen and sulfur, and whereinsaid ring system may be substituted once or more than once by R₁₇;

R₃ is hydrogen or —CH₂R₁₈;

R₁₈ is hydrogen, C₁₋₄alkyl, C₂₋₆alkenyl or C₃₋₆cycloalkyl;

and

R₄ is hydrogen, halogen, hydroxyl, amino, cyano, C₁₋₄alkyl,C₁₋₄halogenalkyl, C₁₋₄ hydroxyalkyl, C₁₋₄alkoxy-C₁₋₄alkyl,amino-C₁₋₄alkyl, C₁₋₄alkyl-amino-C₁₋₄alkyl,di(C₁₋₄alkyl)-amino-C₁₋₄alkyl, C₁₋₄alkoxy, C₁₋₄halogenalkoxy,C₁₋₄alkylamino or di(C₁₋₄alkyl)amino;

or a three- to seven-membered monocyclic aromatic, saturated orunsaturated non-aromatic ring system, wherein said ring system maycontain from 1 to 4 hetero atoms selected from nitrogen, oxygen andsulfur, wherein said ring system may be attached directly or via a C₁₋₂alkylene, and wherein said ring system may be substituted once or morethan once by R₁₉;or

R₃ and R₄ taken together are —CH₂—CH₂—;

R₅ is hydrogen, halogen, hydroxyl, cyano, C₁₋₄alkyl, C₂₋₄alkenyl,C₂₋₄alkinyl or C₁₋₄alkoxy; or C₃₋₄cycloalkyl, wherein one carbon atommay be replaced by an oxygen atom, wherein the C₃₋₄cycloalkyl may beattached directly or via a C₁₋₂alkylene;

R₆, R₁₁, R₁₇ and R₁₉ each independently is halogen, hydroxyl, amino,cyano, nitro, C₁₋₄alkyl, C₁₋₄halogenalkyl, C₁₋₄hydroxyalkyl,C₁₋₄alkoxy-C₁₋₄alkyl, amino-C₁₋₄alkyl, C₁₋₄alkyl-amino-C₁₋₄alkyl,di(C₁₋₄alkyl)-amino-C₁₋₄alkyl, C₁₋₄alkoxy, C₁₋₄halogenalkoxy,C₁₋₄alkylamino or di(C₁₋₄ alkyl)amino;

or C₃₋₆cycloalkyl, wherein one carbon atom may be replaced by an oxygenatom, wherein the C₃₋₆cycloalkyl may be attached directly or via aC₁₋₂alkylene, and wherein the C₃₋₆cycloalkyl may be substituted once ormore than once by halogen;or two R₆, R₁₁, R₁₇ or R₁₉ at the same ring atom together are oxo;or two R₆, R₁₁, R₁₇ or R₁₉ at the same ring carbon atom together withsaid carbon atom form a C₃₋₆cycloalkyl;

R₇, R₁₀, R₁₃ and R₁₆ each independently is halogen, hydroxyl, amino,cyano, nitro, C₁₋₄alkoxy, C₁₋₄halogenalkoxy, C₁₋₄alkylamino ordi(C₁₋₄alkyl)amino;

or C₃₋₆cycloalkyl, wherein one carbon atom may be replaced by an oxygenatom, wherein the C₃₋₆cycloalkyl may be attached directly or via aC₁₋₂alkylene, and wherein the C₃₋₆cycloalkyl may be substituted once ormore than once by halogen;or two R₇, R₁₀, R₁₃ or R₁₆ at the same carbon atom together are oxo;or two R₇, R₁₀, R₁₃ or R₁₆ at the same carbon atom together with saidcarbon atom form a C₃₋₆ cycloalkyl;for use as a medicament.

In a sixth aspect, the invention relates to a compound of formula (I)

or a salt thereof, wherein

R₁ is a five- to six-membered monocyclic saturated or unsaturatednon-aromatic ring system, wherein said ring system may contain from 1 to4 hetero atoms selected from nitrogen, oxygen and sulfur, and whereinsaid ring system may be substituted once or more than once by R₆;

and

R₂ is C₂₋₆alkyl which may be substituted once or more than once by R₇;

or R₂ is —X₁—R₈; —X₁— is —O—, —S— or —N(R₉)—; R₉ is hydrogen orC₁₋₄alkyl; and R₈ is C₁₋₆alkyl which may be substituted once or morethan once by R₁₀;or R₂ is a three- to five-membered monocyclic saturated or unsaturatednon-aromatic ring system, wherein said ring system may contain from 1 to4 hetero atoms selected from nitrogen, oxygen and sulfur, and whereinsaid ring system may be substituted once or more than once by R₁₁;or

R₁ is

wherein the phenyl ring is attached via the bond marked with anasterisk;each R₁₂ independently is hydrogen, halogen, hydroxyl, amino, cyano,nitro, C₁₋₄alkyl, C₁₋₄halogenalkyl, C₁₋₄hydroxyalkyl,C₁₋₄alkoxy-C₁₋₄alkyl, amino-C₁₋₄alkyl, C₁₋₄alkyl-amino-C₁₋₄alkyl,di(C₁₋₄alkyl)-amino-C₁₋₄alkyl, C₁₋₄alkoxy, C₁₋₄halogenalkoxy,C₁₋₄alkylamino or di(C₁₋₄alkyl)amino; or C₃₋₆cycloalkyl, wherein onecarbon atom may be replaced by an oxygen atom, wherein theC₃₋₆cycloalkyl may be attached directly or via a C₁₋₂alkylene, andwherein the C₃₋₆cycloalkyl may be substituted once or more than once byhalogen;and

R₂ is C₂₋₆alkyl which may be substituted once or more than once by R₁₃;

or R₂ is —X₂—R₁₄; —X₂— is —O—, —S— or —N(R₁₅)—; R₁₅ is hydrogen orC₁₋₄alkyl; and R₁₄ is C₁₋₆alkyl which may be substituted once or morethan once by R₁₆;or R₂ is a three- to five-membered monocyclic saturated or unsaturatednon-aromatic ring system, wherein said ring system may contain from 1 to4 hetero atoms selected from nitrogen, oxygen and sulfur, and whereinsaid ring system may be substituted once or more than once by R₁₇;

R₃ is hydrogen or —CH₂R₁₈;

R₁₈ is hydrogen, C₁₋₄alkyl, C₂₋₆alkenyl or C₃₋₆cycloalkyl;

and

R₄ is hydrogen, halogen, hydroxyl, amino, cyano, C₁₋₄alkyl,C₁₋₄halogenalkyl, C₁₋₄ hydroxyalkyl, C₁₋₄alkoxy-C₁₋₄alkyl,amino-C₁₋₄alkyl, C₁₋₄alkyl-amino-C₁₋₄alkyl,di(C₁₋₄alkyl)-amino-C₁₋₄alkyl, C₁₋₄alkoxy, C₁₋₄halogenalkoxy,C₁₋₄alkylamino or di(C₁₋₄alkyl)amino;

or a three- to seven-membered monocyclic aromatic, saturated orunsaturated non-aromatic ring system, wherein said ring system maycontain from 1 to 4 hetero atoms selected from nitrogen, oxygen andsulfur, wherein said ring system may be attached directly or via aC₁₋₂alkylene, and wherein said ring system may be substituted once ormore than once by R₁₉;or

R₃ and R₄ taken together are —CH₂—CH₂—;

R₅ is hydrogen, halogen, hydroxyl, cyano, C₁₋₄alkyl, C₂₋₄alkenyl,C₂₋₄alkinyl or C₁₋₄alkoxy; or C₃₋₄cycloalkyl, wherein one carbon atommay be replaced by an oxygen atom, wherein the C₃₋₄cycloalkyl may beattached directly or via a C₁₋₂alkylene;

R₆, R₁₁, R₁₇ and R₁₉ each independently is halogen, hydroxyl, amino,cyano, nitro, C₁₋₄alkyl, C₁₋₄halogenalkyl, C₁₋₄hydroxyalkyl,C₁₋₄alkoxy-C₁₋₄alkyl, amino-C₁₋₄alkyl, C₁₋₄alkyl-amino-C₁₋₄alkyl,di(C₁₋₄alkyl)-amino-C₁₋₄alkyl, C₁₋₄alkoxy, C₁₋₄halogenalkoxy,C₁₋₄alkylamino or di(C₁₋₄ alkyl)amino;

or C₃₋₆cycloalkyl, wherein one carbon atom may be replaced by an oxygenatom, wherein the C₃₋₆cycloalkyl may be attached directly or via aC₁₋₂alkylene, and wherein the C₃₋₆cycloalkyl may be substituted once ormore than once by halogen;or two R₆, R₁₁, R₁₇ or R₁₉ at the same ring atom together are oxo;or two R₆, R₁₁, R₁₇ or R₁₉ at the same ring carbon atom together withsaid carbon atom form a C₃₋₆cycloalkyl;

R₇, R₁₀, R₁₃ and R₁₆ each independently is halogen, hydroxyl, amino,cyano, nitro, C₁₋₄alkoxy, C₁₋₄halogenalkoxy, C₁₋₄alkylamino ordi(C₁₋₄alkyl)amino;

or C₃₋₆cycloalkyl, wherein one carbon atom may be replaced by an oxygenatom, wherein the C₃₋₆cycloalkyl may be attached directly or via aC₁₋₂alkylene, and wherein the C₃₋₆cycloalkyl may be substituted once ormore than once by halogen;or two R₇, R₁₀, R₁₃ or R₁₆ at the same carbon atom together are oxo;or two R₇, R₁₀, R₁₃ or R₁₆ at the same carbon atom together with saidcarbon atom form a C₃₋₆ cycloalkyl;provided the compound is not

-   2-isopropyl-10-methyl-3-phenylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione;-   10-methyl-2-pentyl-3-phenylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione;-   10-methyl-3-phenyl-2-propylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione;-   2-ethyl-10-methyl-3-phenylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione;-   3-(3,5-dimethylphenyl)-2-ethyl-10-methylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione;-   3-(3,5-dimethylphenyl)-10-methyl-2-pentylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione;-   3-(3,5-dimethylphenyl)-2-isopropyl-10-methylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione;-   3-(3,5-dimethylphenyl)-10-methyl-2-propylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione;-   3-cyclopentyl-2-isopropyl-10-methylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione;-   3-cyclopentyl-10-methyl-2-pentylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione;-   3-cyclopentyl-10-methyl-2-propylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione;-   3-cyclohexyl-10-methyl-2-propylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione;-   3-cyclohexyl-2-isopropyl-10-methylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione;    or-   3-cyclopentyl-2-ethyl-10-methylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione.

Unless specified otherwise, the term “compounds of the invention” refersto compounds of formula (I) and subformulae thereof; salts of thecompounds; hydrates or solvates of the compounds and/or salts; as wellas all stereoisomers (including diastereoisomers), tautomers andisotopically labeled compounds (including deuterium substitutions); aswell as inherently formed moieties (e.g. polymorphs, solvates and/orhydrates).

Unless indicated otherwise, the expressions used in this invention havethe following meaning:

“Alkyl” represents a straight-chain or branched-chain alkyl group and,for example, may be methyl, ethyl, n- or iso-propyl or n-, iso-, sec- ortert-butyl; C₂₋₇alkyl preferably represents a straight-chain orbranched-chain C₂₋₄alkyl with particular preference given to ethyl,n-propyl, iso-propyl and tert-butyl. C₁₋₄alkyl preferably represents astraight-chain or branched-chain C₁₋₃alkyl with particular preferencegiven to methyl, ethyl, n-propyl and iso-propyl.

Each alkyl part of “alkoxy”, “halogenalkyl”, “hydroxyalkyl”,“aminoalkyl”, “alkoxyalkyl” and so on shall have the same meaning asdescribed in the above-mentioned definition of “alkyl”, especiallyregarding linearity and preferential size, unless the size is furtherspecified.

“C₃₋₆cycloalkyl” represents a saturated alicyclic moiety having fromthree to six carbon atoms. This term refers to groups such ascyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl.

A substituent being substituted “once or more than once”, e.g. asdefined in connection with R₁, is preferably substituted by one to threesubstituents.

Halogen is generally fluorine, chlorine, bromine or iodine; preferablyfluorine, chlorine or bromine. Halogenalkyl groups preferably have achain length of 1 to 4 carbon atoms and are, for example, fluoromethyl,difluoromethyl, trifluoromethyl, chloromethyl, dichloromethyl,trichloromethyl, 2,2,2-trifluoroethyl, 2-fluoroethyl, 2-chloroethyl,pentafluoroethyl, 1,1-difluoro-2,2,2-trichloroethyl,2,2,2-trichloroethyl, 1,1,2,2-tetrafluoroethyl,2,2,3,3-tetrafluoropropyl, 2,2,3,3,3-pentafluoropropyl or2,2,3,4,4,4-hexafluorobutyl.

In the context of the invention, the definition of R₁ as a “five- toseven-membered monocyclic saturated or unsaturated non-aromatic ringsystem, wherein said ring system may contain from 1 to 4 hetero atoms”encompasses five- to seven-membered monocyclic non-aromatic hydrocarbongroups and heterocyclic ring systems of the same sizes.

In the context of the invention, the definition of R₂ or R₄ as a “three-to seven-membered monocyclic aromatic, saturated or unsaturatednon-aromatic ring system, wherein said ring system may contain from 1 to4 hetero atoms” encompasses (i) three- to seven-membered monocyclicaromatic or non-aromatic hydrocarbon groups and aromatic or non-aromaticheterocyclic ring systems of the same sizes.

Examples of heterocyclic ring systems are: pyrrole, pyrroline,pyrrolidine, pyrazole, pyrazoline, pyrazolidine, imidazole, imidazoline,imidazolidine, triazole, triazoline, triazolidine, tetrazole, furane,dihydrofurane, tetrahydrofurane, oxadiazole, dioxolane, thiophene,dihydrothiophene, tetrahydrothiophene, oxazole, oxazoline, oxazolidine,isoxazole, isoxazoline, isoxazolidine, thiazole, thiazoline,thiazolidine, isothiazole, isothiazoline, isothiazolidine, thiadiazole,thiadiazoline, thiadiazolidine, pyridine, piperidine, pyridazine,pyrazine, pyrimidine, piperazine, triazine, pyrane, tetrahydropyrane,thiopyrane, tetrahydrothiopyrane, oxazine, thiazine, morpholine.

Compounds of formula I may exist in optically active form or in form ofmixtures of optical isomers, e.g. in form of racemic mixtures ordiastereomeric mixtures. In particular, asymmetrical carbon atom(s) maybe present in the compounds of formula I and their salts. Unlessotherwise provided herein, all optical isomers and their mixtures,including the racemic mixtures, are embraced by the invention.

As used herein, the term “isomers” refers to different compounds thathave the same molecular formula but differ in arrangement andconfiguration of the atoms. Also as used herein, the term “an opticalisomer” or “a stereoisomer” refers to any of the various stereo isomericconfigurations which may exist for a given compound of the invention andincludes geometric isomers. It is understood that a substituent may beattached at a chiral center of a carbon atom. The term “chiral” refersto molecules which have the property of non-superimposability on theirmirror image partner, while the term “achiral” refers to molecules whichare superimposable on their mirror image partner. Therefore, theinvention includes enantiomers, diastereomers or racemates of thecompound. “Enantiomers” are a pair of stereoisomers that arenon-superimposable mirror images of each other. A 1:1 mixture of a pairof enantiomers is a “racemic” mixture. The term is used to designate aracemic mixture where appropriate. “Diastereoisomers” are stereoisomersthat have at least two asymmetric atoms, but which are not mirror-imagesof each other. The absolute stereochemistry is specified according tothe Cahn-Ingold-Prelog R-S system. When a compound is a pure enantiomerthe stereochemistry at each chiral carbon may be specified by either Ror S. Resolved compounds whose absolute configuration is unknown can bedesignated (+) or (−) depending on the direction (dextro- orlevorotatory) which they rotate plane polarized light at the wavelengthof the sodium D line. The compounds described herein may contain one ormore asymmetric centers and may thus give rise to enantiomers,diastereomers, and other stereoisomeric forms that may be defined, interms of absolute stereochemistry, as (R)- or (S)-. Unless otherwiseprovided herein, the invention is meant to include all such possibleisomers, including racemic mixtures, optically pure forms andintermediate mixtures. Optically active (R)- and (S)-isomers may beprepared using chiral synthons or chiral reagents, or resolved usingconventional techniques.

If the compound contains a double bond, the substituent may be E or Zconfiguration.

If the compound contains a disubstituted cycloalkyl, the cycloalkylsubstituent may have a cis- or trans-configuration.

Any asymmetric atom (e.g. carbon or the like) of the compound(s) of theinvention can be present in racemic or enantiomerically enriched, forexample the (R)-, (S)- or (R,S)-configuration. In certain embodiments,each asymmetric atom has at least 50% enantiomeric excess, at least 60%enantiomeric excess, at least 70% enantiomeric excess, at least 80%enantiomeric excess, at least 90% enantiomeric excess, at least 95%enantiomeric excess, or at least 99% enantiomeric excess in the (R)- or(S)-configuration. Substituents at atoms with unsaturated bonds may, ifpossible, be present in cis-(Z)- or trans-(E)-form.

Accordingly, as used herein, a compound of the invention can be in theform of one of the possible isomers, rotamers, atropisomers, tautomersor mixtures thereof, for example, as substantially pure geometric (cisor trans) isomers, diastereomers, optical isomers (antipodes), racematesor mixtures thereof.

Any resulting mixtures of isomers can be separated on the basis of thephysicochemical differences of the constituents, into the pure orsubstantially pure geometric or optical isomers, diastereomers,racemates, for example, by chromatography and/or fractionalcrystallization.

Any resulting racemates of final products or intermediates can beresolved into the optical antipodes by known methods, e.g., byseparation of the diastereomeric salts thereof, obtained with anoptically active acid or base, and liberating the optically activeacidic or basic compound. In particular, a basic moiety may thus beemployed to resolve the compounds of the invention into their opticalantipodes, e.g., by fractional crystallization of a salt formed with anoptically active acid, e.g., tartaric acid, dibenzoyl tartaric acid,diacetyl tartaric acid, di-O,O′-p-toluoyl tartaric acid, mandelic acid,malic acid or camphor-10-sulfonic acid. Racemic products can also beresolved by chiral chromatography, e.g., high pressure liquidchromatography (HPLC) using a chiral adsorbent.

Depending on substituent definition, compounds of formula I may occur invarious tautomeric forms. All tautomeric forms of the compounds offormula I are embraced by the invention. For example, compounds offormula I, in which R₁, R₂, R₄ and R₅ are as defined under formula I,and R₃ is hydrogen, may exist in tautomeric forms (IA), (IB) or (IC):

As used herein, the terms “salt” or “salts” refers to an acid additionor base addition salt of a compound of the invention. “Salts” include inparticular “pharmaceutically acceptable salts”. The term“pharmaceutically acceptable salts” refers to salts that retain thebiological effectiveness and properties of the compounds of thisinvention and, which typically are not biologically or otherwiseundesirable. The compounds of the invention may be capable of formingacid and/or base salts by virtue of the presence of amino and/orcarboxyl groups or groups similar thereto.

Pharmaceutically acceptable acid addition salts can be formed withinorganic acids and organic acids, e.g., acetate, aspartate, benzoate,besylate, bromide/hydrobromide, bicarbonate/carbonate,bisulfate/sulfate, camphorsulfonate, chloride/hydrochloride,chlortheophyllonate, citrate, ethandisulfonate, fumarate, gluceptate,gluconate, glucuronate, hippurate, hydroiodide/iodide, isethionate,lactate, lactobionate, laurylsulfate, malate, maleate, malonate,mandelate, mesylate, methylsulphate, naphthoate, napsylate, nicotinate,nitrate, octadecanoate, oleate, oxalate, palmitate, pamoate,phosphate/hydrogen phosphate/di hydrogen phosphate, polygalacturonate,propionate, stearate, succinate, sulfosalicylate, tartrate, tosylate andtrifluoroacetate salts.

Inorganic acids from which salts can be derived include, for example,hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid,phosphoric acid, and the like.

Organic acids from which salts can be derived include, for example,acetic acid, propionic acid, glycolic acid, oxalic acid, maleic acid,malonic acid, succinic acid, fumaric acid, tartaric acid, citric acid,benzoic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid,toluenesulfonic acid, sulfosalicylic acid, and the like.Pharmaceutically acceptable base addition salts can be formed withinorganic and organic bases.

Inorganic bases from which salts can be derived include, for example,ammonium salts and metals from columns I to XII of the periodic table.In certain embodiments, the salts are derived from sodium, potassium,ammonium, calcium, magnesium, iron, silver, zinc, and copper;particularly suitable salts include ammonium, potassium, sodium, calciumand magnesium salts.

Organic bases from which salts can be derived include, for example,primary, secondary, and tertiary amines, substituted amines includingnaturally occurring substituted amines, cyclic amines, basic ionexchange resins, and the like. Certain organic amines includeisopropylamine, benzathine, cholinate, diethanolamine, diethylamine,lysine, meglumine, piperazine and tromethamine.

The pharmaceutically acceptable salts of the invention can besynthesized from a basic or acidic moiety, by conventional chemicalmethods. Generally, such salts can be prepared by reacting free acidforms of these compounds with a stoichiometric amount of the appropriatebase (such as Na, Ca, Mg, or K hydroxide, carbonate, bicarbonate or thelike), or by reacting free base forms of these compounds with astoichiometric amount of the appropriate acid. Such reactions aretypically carried out in water or in an organic solvent, or in a mixtureof the two. Generally, use of non-aqueous media like ether, ethylacetate, ethanol, isopropanol, or acetonitrile is desirable, wherepracticable. Lists of additional suitable salts can be found, e.g., in“Remington's Pharmaceutical Sciences”, 20th ed., Mack PublishingCompany, Easton, Pa., (1985); and in “Handbook of Pharmaceutical Salts:Properties, Selection, and Use” by Stahl and Wermuth (Wiley-VCH,Weinheim, Germany, 2002).

When both a basic group and an acid group are present in the samemolecule, the compounds of the invention may also form internal salts,e.g., zwitterionic molecules.

Any formula given herein is also intended to represent unlabeled formsas well as isotopically labeled forms of the compounds. Isotopicallylabeled compounds have structures depicted by the formulas given hereinexcept that one or more atoms are replaced by an atom having a selectedatomic mass or mass number. Examples of isotopes that can beincorporated into compounds of the invention include isotopes ofhydrogen, carbon, nitrogen, oxygen, phosphorous, fluorine, and chlorine,such as ²H, ³H, ¹¹C, ¹³C, ¹⁴C, ¹⁵N, ¹⁸F ³¹P, ³²P, ³⁵S, ³⁶Cl, ¹²⁵Irespectively. The invention includes various isotopically labeledcompounds as defined herein, for example those into which radioactiveisotopes, such as ³H and ¹⁴C, or those into which non-radioactiveisotopes, such as ²H and ¹³C are present. Such isotopically labelledcompounds are useful in metabolic studies (with ¹⁴C), reaction kineticstudies (with, for example ²H or ³H), detection or imaging techniques,such as positron emission tomography (PET) or single-photon emissioncomputed tomography (SPECT) including drug or substrate tissuedistribution assays, or in radioactive treatment of patients. Inparticular, an ¹⁸F or labeled compound may be particularly desirable forPET or SPECT studies. Isotopically-labeled compounds of formula (I) cangenerally be prepared by conventional techniques known to those skilledin the art or by processes analogous to those described in theaccompanying Examples and Preparations using an appropriateisotopically-labeled reagents in place of the non-labeled reagentpreviously employed.

Further, substitution with heavier isotopes, particularly deuterium(i.e., ²H or D) may afford certain therapeutic advantages resulting fromgreater metabolic stability, for example increased in vivo half-life orreduced dosage requirements or an improvement in therapeutic index. Itis understood that deuterium in this context is regarded as asubstituent of a compound of the formula (I). The concentration of sucha heavier isotope, specifically deuterium, may be defined by theisotopic enrichment factor. The term “isotopic enrichment factor” asused herein means the ratio between the isotopic abundance and thenatural abundance of a specified isotope. If a substituent in a compoundof this invention is denoted deuterium, such compound has an isotopicenrichment factor for each designated deuterium atom of at least 3500(52.5% deuterium incorporation at each designated deuterium atom), atleast 4000 (60% deuterium incorporation), at least 4500 (67.5% deuteriumincorporation), at least 5000 (75% deuterium incorporation), at least5500 (82.5% deuterium incorporation), at least 6000 (90% deuteriumincorporation), at least 6333.3 (95% deuterium incorporation), at least6466.7 (97% deuterium incorporation), at least 6600 (99% deuteriumincorporation), or at least 6633.3 (99.5% deuterium incorporation).

Pharmaceutically acceptable solvates in accordance with the inventioninclude those wherein the solvent of crystallization may be isotopicallysubstituted, e.g. D₂O, d₆-acetone, d₆-DMSO.

Compounds of the invention that contain groups capable of acting asdonors and/or acceptors for hydrogen bonds may be capable of formingco-crystals with suitable co-crystal formers. These co-crystals may beprepared from compounds of formula (I) by known co-crystal formingprocedures. Such procedures include grinding, heating, co-subliming,co-melting, or contacting in solution compounds of formula I with theco-crystal former under crystallization conditions and isolatingco-crystals thereby formed. Suitable co-crystal formers include thosedescribed in WO 2004/078163. Hence the invention further providesco-crystals comprising a compound of formula (I).

The invention also envisages the use of pro-drugs of the compounds ofthe invention that convert in vivo to the compounds of the invention. Apro-drug is an active or inactive compound that is modified chemicallythrough in vivo physiological action, such as hydrolysis, metabolism andthe like, into a compound of the invention following administration ofthe prodrug to a subject. The suitability and techniques involved inmaking and using pro-drugs are well known by those skilled in the art.Prodrugs can be conceptually divided into two non-exclusive categories,bioprecursor prodrugs and carrier prodrugs. See The Practice ofMedicinal Chemistry, Ch. 31-32 (Ed. Wermuth, Academic Press, San Diego,Calif., 2001).

Furthermore, the compounds of the invention, including their salts, canalso be obtained in the form of their hydrates, or include othersolvents used for their crystallization. The compounds of the inventionmay inherently or by design form solvates with pharmaceuticallyacceptable solvents (including water); therefore, it is intended thatthe invention embrace both solvated and unsolvated forms. The term“solvate” refers to a molecular complex of a compound of the invention(including pharmaceutically acceptable salts thereof) with one or moresolvent molecules. Such solvent molecules are those commonly used in thepharmaceutical art, which are known to be innocuous to the recipient,e.g., water, ethanol, and the like. The term “hydrate” refers to thecomplex where the solvent molecule is water. The compounds of theinvention, including salts, hydrates and solvates thereof, mayinherently or by design form polymorphs.

Preferred substituents, preferred ranges of numerical values orpreferred ranges of the radicals present in compounds of the formula Iand the corresponding intermediate compounds are defined below.

The definition of the substituents applies to compounds of the first,second and third aspect; i.e. compounds of formula (I) for use as amedicament for the treatment of a disease caused by a nonsense mutation,compounds of formula (I) for use as a medicament and compounds offormula (I) per se, respectively.

The definition of the substituents applies to the end-products as wellas to the corresponding intermediates.

The definitions of the substituents may be combined at will, e.g.preferred substituents R₁ and particularly preferred substituents R₂.

In one embodiment, R₁ is a five- to six-membered monocyclic saturated orunsaturated non-aromatic ring system, wherein said ring system maycontain from 1 to 4 hetero atoms selected from nitrogen, oxygen andsulfur, and wherein said ring system may be substituted once or morethan once by R₆;

and

R₂ is C₂₋₆alkyl which may be substituted once or more than once by R₇;

or R₂ is —X₁—R₈; —X₁— is —O—, —S— or —N(R₉)—; R₉ is hydrogen orC₁₋₄alkyl; and R₈ is C₁₋₆alkyl which may be substituted once or morethan once by R₁₀;or R₂ is a three- to five-membered monocyclic saturated or unsaturatednon-aromatic ring system, wherein said ring system may contain from 1 to4 hetero atoms selected from nitrogen, oxygen and sulfur, and whereinsaid ring system may be substituted once or more than once by R₁₁;or

R₁ is

wherein the phenyl ring is attached via the bond marked with anasterisk;each R₁₂ independently is hydrogen, halogen, hydroxyl, amino, cyano,nitro, C₁₋₄alkyl, C₁₋₄ halogenalkyl, C₁₋₄hydroxyalkyl,C₁₋₄alkoxy-C₁₋₄alkyl, amino-C₁₋₄alkyl, C₁₋₄alkyl-amino-C₁₋₄ alkyl,di(C₁₋₄alkyl)-amino-C₁₋₄alkyl, C₁₋₄alkoxy, C₁₋₄halogenalkoxy,C₁₋₄alkylamino or di(C₁₋₄alkyl)amino; or C₃₋₆cycloalkyl, wherein onecarbon atom may be replaced by an oxygen atom, wherein theC₃₋₆cycloalkyl may be attached directly or via a C₁₋₂alkylene, andwherein the C₃₋₆cycloalkyl may be substituted once or more than once byhalogen;and

R₂ is C₂₋₇alkyl which may be substituted once or more than once by R₁₃;

or R₂ is —X₂—R₁₄; —X₂— is —O—, —S— or —N(R₁₅)—; R₁₅ is hydrogen orC₁₋₄alkyl; and R₁₄ is C₁₋₆alkyl which may be substituted once or morethan once by R₁₆;or R₂ is a three- to five-membered monocyclic saturated or unsaturatednon-aromatic ring system, wherein said ring system may contain from 1 to4 hetero atoms selected from nitrogen, oxygen and sulfur, and whereinsaid ring system may be substituted once or more than once by R₁₇;

R₃ is hydrogen or —CH₂R₁₈;

R₁₈ is hydrogen, C₁₋₄alkyl, C₂₋₆alkenyl, C₃₋₆cycloalkyl,C₁₋₃alkoxyC₁₋₃alkyl, hydroxyC₁₋₃alkyl, or aminoC₁₋₃alkyl;

and

R₄ is hydrogen, halogen, hydroxyl, amino, cyano, C₁₋₄alkyl,C₁₋₄halogenalkyl, C₁₋₄ hydroxyalkyl, C₁₋₄alkoxy-C₁₋₄alkyl,amino-C₁₋₄alkyl, C₁₋₄alkyl-amino-C₁₋₄alkyl,di(C₁₋₄alkyl)-amino-C₁₋₄alkyl, C₁₋₄alkoxy, C₁₋₄halogenalkoxy,C₁₋₄alkylamino or di(C₁₋₄alkyl)amino;

or a three- to seven-membered monocyclic aromatic, saturated orunsaturated non-aromatic ring system, wherein said ring system maycontain from 1 to 4 hetero atoms selected from nitrogen, oxygen andsulfur, wherein said ring system may be attached directly or via a C₁₋₂alkylene, and wherein said ring system may be substituted once or morethan once by R₁₉;or

R₃ and R₄ taken together are —CH₂—CH₂—;

R₅ is hydrogen, halogen, hydroxyl, cyano, C₁₋₄alkyl, C₂₋₄alkenyl,C₂₋₄alkinyl or C₁₋₄alkoxy; or C₃₋₄cycloalkyl, wherein one carbon atommay be replaced by an oxygen atom, wherein the C₃₋₄cycloalkyl may beattached directly or via a C₁₋₂alkylene;

R₆, R₁₁, R₁₇ and R₁₉ each independently is halogen, hydroxyl, amino,cyano, nitro, C₁₋₄alkyl, C₁₋₄halogenalkyl, C₁₋₄hydroxyalkyl,C₁₋₄alkoxy-C₁₋₄alkyl, amino-C₁₋₄alkyl, C₁₋₄alkyl-amino-C₁₋₄ alkyl,di(C₁₋₄alkyl)-amino-C₁₋₄alkyl, C₁₋₄alkoxy, C₁₋₄halogenalkoxy,C₁₋₄alkylamino or di(C₁₋₄ alkyl)amino;

or C₃₋₆cycloalkyl, wherein one carbon atom may be replaced by an oxygenatom, wherein the C₃₋₆cycloalkyl may be attached directly or via aC₁₋₂alkylene, and wherein the C₃₋₆cycloalkyl may be substituted once ormore than once by halogen;or two R₆, R₁₁, R₁₇ or R₁₉ at the same ring atom together are oxo;or two R₆, R₁₁, R₁₇ or R₁₉ at the same ring carbon atom together withsaid carbon atom form a C₃₋₆cycloalkyl;

R₇, R₁₀, R₁₃ and R₁₆ each independently is halogen, hydroxyl, amino,cyano, nitro, C₁₋₄alkoxy, C₁₋₄halogenalkoxy, C₁₋₄alkylamino ordi(C₁₋₄alkyl)amino;

or C₃₋₆cycloalkyl, wherein one carbon atom may be replaced by an oxygenatom, wherein the C₃₋₆cycloalkyl may be attached directly or via aC₁₋₂alkylene, and wherein the C₃₋₆cycloalkyl may be substituted once ormore than once by halogen;or two R₇, R₁₀, R₁₃ or R₁₆ at the same carbon atom together are oxo;or two R₇, R₁₀, R₁₃ or R₁₆ at the same carbon atom together with saidcarbon atom form a C₃₋₆ cycloalkyl.

In one embodiment, R₁ is

wherein the phenyl ring is attached via the bond marked with anasterisk;each R₁₂ independently is hydrogen, halogen, hydroxyl, amino, cyano,nitro, C₁₋₄alkyl, C₁₋₄ halogenalkyl, C₁₋₄hydroxyalkyl,C₁₋₄alkoxy-C₁₋₄alkyl, amino-C₁₋₄alkyl, C₁₋₄alkyl-amino-C₁₋₄alkyl,di(C₁₋₄alkyl)-amino-C₁₋₄alkyl, C₁₋₄alkoxy, C₁₋₄halogenalkoxy,C₁₋₄alkylamino or di(C₁₋₄alkyl)amino; or C₃₋₆cycloalkyl, wherein onecarbon atom may be replaced by an oxygen atom, wherein theC₃₋₆cycloalkyl may be attached directly or via a C₁₋₂alkylene, andwherein the C₃₋₆cycloalkyl may be substituted once or more than once byhalogen;and

R₂ is C₂₋₇alkyl which may be substituted once or more than once by R₁₃;

or R₂ is —X₂—R₁₄; —X₂— is —O—, —S— or —N(R₁₅)—; R₁₅ is hydrogen orC₁₋₄alkyl; and R₁₄ is C₁₋₆alkyl which may be substituted once or morethan once by R₁₆;or R₂ is a three- to five-membered monocyclic saturated or unsaturatednon-aromatic ring system, wherein said ring system may contain from 1 to4 hetero atoms selected from nitrogen, oxygen and sulfur, and whereinsaid ring system may be substituted once or more than once by R₁₇;

R₃ is hydrogen or —CH₂R₁₈;

R₁₈ is hydrogen, C₁₋₄alkyl, C₂₋₆alkenyl, C₃₋₆cycloalkyl,C₁₋₃alkoxyC₁₋₃alkyl, hydroxyC₁₋₃alkyl, or aminoC₁₋₃alkyl;

and

R₄ is hydrogen, halogen, hydroxyl, amino, cyano, C₁₋₄alkyl,C₁₋₄halogenalkyl, C₁₋₄ hydroxyalkyl, C₁₋₄alkoxy-C₁₋₄alkyl,amino-C₁₋₄alkyl, C₁₋₄alkyl-amino-C₁₋₄alkyl,di(C₁₋₄alkyl)-amino-C₁₋₄alkyl, C₁₋₄alkoxy, C₁₋₄halogenalkoxy,C₁₋₄alkylamino or di(C₁₋₄alkyl)amino;

or a three- to seven-membered monocyclic aromatic, saturated orunsaturated non-aromatic ring system, wherein said ring system maycontain from 1 to 4 hetero atoms selected from nitrogen, oxygen andsulfur, wherein said ring system may be attached directly or via a C₁₋₂alkylene, and wherein said ring system may be substituted once or morethan once by R₁₉;or

R₃ and R₄ taken together are —CH₂—CH₂—;

R₅ is hydrogen, halogen, hydroxyl, cyano, C₁₋₄alkyl, C₂₋₄alkenyl,C₂₋₄alkinyl or C₁₋₄alkoxy; or C₃₋₄cycloalkyl, wherein one carbon atommay be replaced by an oxygen atom, wherein the C₃₋₄cycloalkyl may beattached directly or via a C₁₋₂alkylene;

R₁₃ and R₁₆ each independently is halogen, hydroxyl, amino, cyano,nitro, C₁₋₄alkoxy, C₁₋₄ halogenalkoxy, C₁₋₄alkylamino ordi(C₁₋₄alkyl)amino;

or C₃₋₆cycloalkyl, wherein one carbon atom may be replaced by an oxygenatom, wherein the C₃₋₆cycloalkyl may be attached directly or via aC₁₋₂alkylene, and wherein the C₃₋₆cycloalkyl may be substituted once ormore than once by halogen;or two R₁₃ or R₁₆ at the same carbon atom together are oxo;or two R₁₃ or R₁₆ at the same carbon atom together with said carbon atomform a C₃₋₆ cycloalkyl;

R₁₇ and R₁₉ each independently is halogen, hydroxyl, amino, cyano,nitro, C₁₋₄alkyl, C₁₋₄ halogenalkyl, C₁₋₄hydroxyalkyl,C₁₋₄alkoxy-C₁₋₄alkyl, amino-C₁₋₄alkyl, C₁₋₄alkyl-amino-C₁₋₄alkyl,di(C₁₋₄alkyl)-amino-C₁₋₄alkyl, C₁₋₄alkoxy, C₁₋₄halogenalkoxy,C₁₋₄alkylamino or di(C₁₋₄ alkyl)amino;

or C₃₋₆cycloalkyl, wherein one carbon atom may be replaced by an oxygenatom, wherein the C₃₋₆cycloalkyl may be attached directly or via aC₁₋₂alkylene, and wherein the C₃₋₆cycloalkyl may be substituted once ormore than once by halogen;or two R₁₇ or R₁₉ at the same ring atom together are oxo;or two R₁₇ or R₁₉ at the same ring carbon atom together with said carbonatom form a C₃₋₆ cycloalkyl.

In one embodiment, R₁ is a five- to six-membered monocyclic saturated orunsaturated non-aromatic ring system, wherein said ring system maycontain from 1 to 4 hetero atoms selected from nitrogen, oxygen andsulfur, and wherein said ring system may be substituted once or morethan once by R₆;

and

R₂ is C₂₋₆alkyl which may be substituted once or more than once by R₇;

or R₂ is —X₁—R₈; —X₁— is —O—, —S— or —N(R₉)—; R₉ is hydrogen orC₁₋₄alkyl; and R₈ is C₁₋₆alkyl which may be substituted once or morethan once by R₁₀;or R₂ is a three- to five-membered monocyclic saturated or unsaturatednon-aromatic ring system, wherein said ring system may contain from 1 to4 hetero atoms selected from nitrogen, oxygen and sulfur, and whereinsaid ring system may be substituted once or more than once by R₁₁;

R₃ is hydrogen or —CH₂R₁₈;

R₁₈ is hydrogen, C₁₋₄alkyl, C₂₋₆alkenyl or C₃₋₆cycloalkyl;

and

R₄ is hydrogen, halogen, hydroxyl, amino, cyano, C₁₋₄alkyl,C₁₋₄halogenalkyl, C₁₋₄ hydroxyalkyl, C₁₋₄alkoxy-C₁₋₄alkyl,amino-C₁₋₄alkyl, C₁₋₄alkyl-amino-C₁₋₄alkyl,di(C₁₋₄alkyl)-amino-C₁₋₄alkyl, C₁₋₄alkoxy, C₁₋₄halogenalkoxy,C₁₋₄alkylamino or di(C₁₋₄alkyl)amino;

or a three- to seven-membered monocyclic aromatic, saturated orunsaturated non-aromatic ring system, wherein said ring system maycontain from 1 to 4 hetero atoms selected from nitrogen, oxygen andsulfur, wherein said ring system may be attached directly or via a C₁₋₂alkylene, and wherein said ring system may be substituted once or morethan once by R₁₉;or

R₃ and R₄ taken together are —CH₂—CH₂—;

R₅ is hydrogen, halogen, hydroxyl, cyano, C₁₋₄alkyl, C₂₋₄alkenyl,C₂₋₄alkinyl or C₁₋₄alkoxy; or C₃₋₄cycloalkyl, wherein one carbon atommay be replaced by an oxygen atom, wherein the C₃₋₄cycloalkyl may beattached directly or via a C₁₋₂alkylene;

R₇ and R₁₀ each independently is halogen, hydroxyl, amino, cyano, nitro,C₁₋₄alkoxy, C₁₋₄ halogenalkoxy, C₁₋₄alkylamino or di(C₁₋₄alkyl)amino;

or C₃₋₆cycloalkyl, wherein one carbon atom may be replaced by an oxygenatom, wherein the C₃₋₆cycloalkyl may be attached directly or via aC₁₋₂alkylene, and wherein the C₃₋₆cycloalkyl may be substituted once ormore than once by halogen;or two R₇ or R₁₀ at the same carbon atom together are oxo;or two R₇ or R₁₀ at the same carbon atom together with said carbon atomform a C₃₋₆ cycloalkyl;

R₆, R₁₁ and R₁₉ each independently is halogen, hydroxyl, amino, cyano,nitro, C₁₋₄alkyl, C₁₋₄ halogenalkyl, C₁₋₄hydroxyalkyl,C₁₋₄alkoxy-C₁₋₄alkyl, amino-C₁₋₄alkyl, C₁₋₄alkyl-amino-C₁₋₄alkyl,di(C₁₋₄alkyl)-amino-C₁₋₄alkyl, C₁₋₄alkoxy, C₁₋₄halogenalkoxy,C₁₋₄alkylamino or di(C₁₋₄ alkyl)amino;

or C₃₋₆cycloalkyl, wherein one carbon atom may be replaced by an oxygenatom, wherein the C₃₋₆cycloalkyl may be attached directly or via aC₁₋₂alkylene, and wherein the C₃₋₆cycloalkyl may be substituted once ormore than once by halogen;or two R₆, R₁₁ or R₁₉ at the same ring atom together are oxo;or two R₆, R₁₁ or R₁₉ at the same ring carbon atom together with saidcarbon atom form a C₃₋₆ cycloalkyl.

In one embodiment, R₁ is a five- to six-membered monocyclic saturated orunsaturated non-aromatic ring system, wherein said ring system maycontain from 1 to 4 hetero atoms selected from nitrogen, oxygen andsulfur, and wherein said ring system may be substituted once or morethan once by R₆; each R₆ independently is halogen, hydroxyl, amino,cyano, nitro, C₁₋₄alkyl, C₁₋₄halogenalkyl, C₁₋₄hydroxyalkyl,C₁₋₄alkoxy-C₁₋₄alkyl, amino-C₁₋₄alkyl, C₁₋₄ alkyl-amino-C₁₋₄alkyl,di(C₁₋₄alkyl)-amino-C₁₋₄alkyl, C₁₋₄alkoxy, C₁₋₄halogenalkoxy, C₁₋₄alkylamino or di(C₁₋₄alkyl)amino; or C₃₋₆cycloalkyl, wherein one carbonatom may be replaced by an oxygen atom, wherein the C₃₋₆cycloalkyl maybe attached directly or via a C₁₋₂ alkylene, and wherein theC₃₋₆cycloalkyl may be substituted once or more than once by halogen; ortwo R₆ at the same ring atom together are oxo; or two R₆ at the samering carbon atom together with said carbon atom form a C₃₋₆cycloalkyl.

In one embodiment, R₁ is a five- to six-membered monocyclic saturated orunsaturated non-aromatic ring system, wherein said ring system maycontain from 1 to 4 hetero atoms selected from nitrogen, oxygen andsulfur, and wherein said ring system may be substituted once or morethan once by R₆; each R₆ independently is halogen, hydroxyl, amino,cyano, nitro, C₁₋₄alkyl, C₁₋₄halogenalkyl, C₁₋₄alkoxy or C₃₋₆cycloalkyl.

In one embodiment, R₁ is

wherein the phenyl ring is attached via the bond marked with anasterisk;each R₁₂ independently is hydrogen, halogen, hydroxyl, amino, cyano,nitro, C₁₋₄alkyl, C₁₋₄halogenalkyl, C₁₋₄alkoxy; or C₃₋₆cycloalkyl.

In one embodiment, R₂ is C₂₋₇alkyl which may be substituted once or morethan once by R₇.

In one embodiment, R₂ is C₂₋₆alkyl which may be substituted once or morethan once by R₇.

In one embodiment, R₂ is C₂₋₆alkyl which may be substituted once or morethan once by R₇;

each R₇ independently is halogen, hydroxyl, amino, cyano, nitro,C₁₋₄alkoxy or C₃₋₆cycloalkyl.

In one embodiment, R₂ is —X₁—R₈; —X₁— is —O—, —S— or —N(R₉)—; R₉ ishydrogen or C₁₋₄alkyl; and R₈ is C₁₋₆alkyl which may be substituted onceor more than once by R₁₀.

In one embodiment, R₂ is —X₁—R₈; —X₁— is —O—, —S— or —N(R₉)—; R₉ ishydrogen or C₁₋₄alkyl; and R₈ is C₁₋₆alkyl which may be substituted onceor more than once by R₁₀; each R₁₀ independently is halogen, hydroxyl,amino, cyano, nitro, C₁₋₄alkoxy or C₃₋₆cycloalkyl.

In one embodiment, R₂ is —X₁—R₈; —X₁— is —O— or —S—; and R₈ is C₁₋₆alkylwhich may be substituted once or more than once by R₁₀; each R₁₀independently is halogen, hydroxyl, amino, cyano, nitro, C₁₋₄alkoxy orC₃₋₆cycloalkyl.

In one embodiment, R₂ is —X₁—R₈; —X₁— is —O— or —S—; and R₈ isC₁₋₆alkyl.

In one embodiment, R₂ is —X₁—R₈; —X₁— is —N(R₉)—; R₉ is hydrogen orC₁₋₄alkyl; and R₈ is C₁₋₆alkyl which may be substituted once or morethan once by R₁₀; each R₁₀ independently is halogen, hydroxyl, amino,cyano, nitro, C₁₋₄alkoxy or C₃₋₆cycloalkyl.

In one embodiment, R₂ is —X₁—R₈; —X₁— is —N(R₉)—; R₉ is C₁₋₄alkyl; andR₈ is C₁₋₆alkyl.

In one embodiment, or R₂ is a three- to five-membered monocyclicsaturated or unsaturated non-aromatic ring system, wherein said ringsystem may contain from 1 to 4 hetero atoms selected from nitrogen,oxygen and sulfur, and wherein said ring system may be substituted onceor more than once by R₁₁.

In one embodiment, or R₂ is a three- to five-membered monocyclicsaturated or unsaturated non-aromatic ring system, wherein said ringsystem may contain from 1 to 4 hetero atoms selected from nitrogen,oxygen and sulfur, and wherein said ring system may be substituted onceor more than once by R₁₁; each R₁₁ independently is halogen, hydroxyl,amino, cyano, nitro, C₁₋₄alkyl, C₁₋₄alkoxy or C₃₋₆cycloalkyl.

In one embodiment, R₂ is C₂₋₆alkyl which may be substituted once or morethan once by R₁₃.

In one embodiment, R₂ is C₂₋₆alkyl which may be substituted once or morethan once by R₁₃; each R₁₃ independently is halogen, hydroxyl, amino,cyano, nitro, C₁₋₄alkoxy or C₃₋₆cycloalkyl.

In one embodiment, R₂ is —X₂—R₁₄; —X₂— is —O—, —S— or —N(R₁₅)—; R₁₅ ishydrogen or C₁₋₄alkyl; and R₁₄ is C₁₋₆alkyl which may be substitutedonce or more than once by R₁₆.

In one embodiment, R₂ is —X₂—R₁₄; —X₂— is —O—, —S— or —N(R₁₅)—; R₁₅ ishydrogen or C₁₋₄alkyl; and R₁₄ is C₁₋₆alkyl which may be substitutedonce or more than once by R₁₆; each R₁₆ independently is halogen,hydroxyl, amino, cyano, nitro, C₁₋₄alkoxy or C₃₋₆cycloalkyl.

In one embodiment, R₂ is —X₂—R₁₄; —X₂— is —O— or —S—; and R₁₄ isC₁₋₆alkyl which may be substituted once or more than once by R₁₆; eachR₁₆ independently is halogen, hydroxyl, amino, cyano, nitro, C₁₋₄alkoxyor C₃₋₆cycloalkyl.

In one embodiment, R₂ is —X₂—R₁₄; —X₂— is —O— or —S—; and R₁₄ isC₁₋₆alkyl.

In one embodiment, R₂ is —X₂—R₁₄; —X₂— is —N(R₁₅)—; R₁₅ is hydrogen orC₁₋₄alkyl; and R₁₄ is C₁₋₆alkyl which may be substituted once or morethan once by R₁₆; each R₁₆ independently is halogen, hydroxyl, amino,cyano, nitro, C₁₋₄alkoxy or C₃₋₆cycloalkyl.

In one embodiment, R₂ is —X₂—R₁₄; —X₂— is —N(R₁₅)—; R₁₅ is C₁₋₄alkyl;and R₁₄ is C₁₋₆alkyl.

In one embodiment, or R₂ is a three- to five-membered monocyclicsaturated or unsaturated non-aromatic ring system, wherein said ringsystem may contain from 1 to 4 hetero atoms selected from nitrogen,oxygen and sulfur, and wherein said ring system may be substituted onceor more than once by R₁₇.

In one embodiment, or R₂ is a three- to five-membered monocyclicsaturated or unsaturated non-aromatic ring system, wherein said ringsystem may contain from 1 to 4 hetero atoms selected from nitrogen,oxygen and sulfur, and wherein said ring system may be substituted onceor more than once by R₁₇; each R₁₇ independently is halogen, hydroxyl,amino, cyano, nitro, C₁₋₄alkyl, C₁₋₄alkoxy or C₃₋₆cycloalkyl.

In one embodiment, R₃ is hydrogen or —CH₂R₁₈; R₁₈ is hydrogen,C₁₋₄alkyl, C₂₋₆alkenyl or C₃₋₆ cycloalkyl; and R₄ is hydrogen, halogen,hydroxyl, amino, cyano, C₁₋₄alkyl, C₁₋₄halogenalkyl, C₁₋₄hydroxyalkyl,C₁₋₄alkoxy-C₁₋₄alkyl, amino-C₁₋₄alkyl, C₁₋₄alkyl-amino-C₁₋₄alkyl,di(C₁₋₄alkyl)-amino-C₁₋₄alkyl, C₁₋₄alkoxy, C₁₋₄halogenalkoxy,C₁₋₄alkylamino or di(C₁₋₄alkyl)amino;

or a three- to seven-membered monocyclic aromatic, saturated orunsaturated non-aromatic ring system, wherein said ring system maycontain from 1 to 4 hetero atoms selected from nitrogen, oxygen andsulfur, wherein said ring system may be attached directly or via a C₁₋₂alkylene, and wherein said ring system may be substituted once or morethan once by R₁₉;each R₁₉ independently is halogen, hydroxyl, amino, cyano, nitro,C₁₋₄alkyl, C₁₋₄halogenalkyl, C₁₋₄hydroxyalkyl, C₁₋₄alkoxy-C₁₋₄alkyl,amino-C₁₋₄alkyl, C₁₋₄alkyl-amino-C₁₋₄alkyl,di(C₁₋₄alkyl)-amino-C₁₋₄alkyl, C₁₋₄alkoxy, C₁₋₄halogenalkoxy,C₁₋₄alkylamino or di(C₁₋₄alkyl)amino; or C₃₋₆ cycloalkyl, wherein onecarbon atom may be replaced by an oxygen atom, wherein the C₃₋₆cycloalkyl may be attached directly or via a C₁₋₂alkylene, and whereinthe C₃₋₆cycloalkyl may be substituted once or more than once by halogen;or two R₁₉ at the same ring atom together are oxo; or two R₁₉ at thesame ring carbon atom together with said carbon atom form a C₃₋₆cycloalkyl.

In one embodiment, R₄ is hydrogen.

In one embodiment, R₃ is hydrogen or —CH₂R₁₈; R₁₈ is hydrogen,C₁₋₄alkyl, C₂₋₆alkenyl or C₃₋₆cycloalkyl; and R₄ is hydrogen, halogen,hydroxyl, amino, cyano, C₁₋₄alkyl, C₁₋₄halogenalkyl, C₁₋₄alkoxy, or athree- to seven-membered monocyclic aromatic, saturated or unsaturatednon-aromatic ring system, wherein said ring system may contain from 1 to4 hetero atoms selected from nitrogen, oxygen and sulfur.

In one embodiment, R₃ is hydrogen.

In one embodiment, R₃ is —CH₂R₁₈; R₁₈ is hydrogen, C₁₋₄alkyl,C₂₋₆alkenyl, or C₃₋₆cycloalkyl.

In one embodiment, R₃ is —CH₂R₁₈; R₁₈ is hydrogen, C₁₋₄alkyl,C₂₋₆alkenyl, C₃₋₆cycloalkyl, C₁₋₃alkoxyC₁₋₃alkyl, hydroxyC₁₋₃alkyl, oraminoC₁₋₃alkyl.

In one embodiment, R₃ is —CH₂R₁₈; and R₁₈ is hydrogen.

In one embodiment, R₃ and R₄ taken together are —CH₂—CH₂—.

In one embodiment, R₅ is hydrogen, halogen, hydroxyl, cyano, C₁₋₄alkyl,C₂₋₄alkenyl, C₂₋₄alkinyl or C₁₋₄alkoxy; or C₃₋₄cycloalkyl, wherein onecarbon atom may be replaced by an oxygen atom, wherein theC₃₋₄cycloalkyl may be attached directly or via a C₁₋₂alkylene.

In one embodiment, R₅ is hydrogen.

In one embodiment, R₁ is

wherein the phenyl ring is attached via the bond marked with anasterisk;each R₁₂ independently is hydrogen, halogen, hydroxyl, amino, cyano,nitro, C₁₋₄alkyl, C₁₋₄halogenalkyl, C₁₋₄alkoxy; or C₃₋₆cycloalkyl;and

R₂ is C₂₋₇alkyl which may be substituted once or more than once by R₁₃;

or R₂ is —X₂—R₁₄; —X₂— is —O—, —S— or —N(R₁₅)—; R₁₅ is hydrogen orC₁₋₄alkyl; and R₁₄ is C₁₋₆alkyl which may be substituted once or morethan once by R₁₆; each R₁₆ independently is halogen, hydroxyl, amino,cyano, nitro, C₁₋₄alkoxy or C₃₋₆cycloalkyl;or R₂ is a three- to five-membered monocyclic saturated or unsaturatednon-aromatic ring system, wherein said ring system may contain from 1 to4 hetero atoms selected from nitrogen, oxygen and sulfur, and whereinsaid ring system may be substituted once or more than once by R₁₇;

R₃ is —CH₂R₁₈; and R₁₈ is hydrogen;

R₄ and R₅ are both hydrogen;

each R₁₃ independently is halogen, hydroxyl, amino, cyano, nitro,C₁₋₄alkoxy or C₃₋₆cycloalkyl;each R₁₇ independently is halogen, hydroxyl, amino, cyano, nitro,C₁₋₄alkyl, C₁₋₄alkoxy or C₃₋₆ cycloalkyl.

In one embodiment, R₁ is

wherein the phenyl ring is attached via the bond marked with anasterisk;each R₁₂ independently is hydrogen, halogen, hydroxyl, amino, cyano,nitro, C₁₋₄alkyl, C₁₋₄halogenalkyl, C₁₋₄alkoxy; or C₃₋₆cycloalkyl;and

R₂ is C₂₋₆alkyl which may be substituted once or more than once by R₁₃;

or R₂ is —X₂—R₁₄; —X₂— is —O—, —S— or —N(R₁₅)—; R₁₅ is hydrogen orC₁₋₄alkyl; and R₁₄ is C₁₋₆alkyl which may be substituted once or morethan once by R₁₆; each R₁₆ independently is halogen, hydroxyl, amino,cyano, nitro, C₁₋₄alkoxy or C₃₋₆cycloalkyl;or R₂ is a three- to five-membered monocyclic saturated or unsaturatednon-aromatic ring system, wherein said ring system may contain from 1 to4 hetero atoms selected from nitrogen, oxygen and sulfur, and whereinsaid ring system may be substituted once or more than once by R₁₇;

R₃ is —CH₂R₁₈; and R₁₈ is hydrogen;

R₄ and R₅ are both hydrogen;

each R₁₃ independently is halogen, hydroxyl, amino, cyano, nitro,C₁₋₄alkoxy or C₃₋₆cycloalkyl;each R₁₇ independently is halogen, hydroxyl, amino, cyano, nitro,C₁₋₄alkyl, C₁₋₄alkoxy or C₃₋₆ cycloalkyl.

In one embodiment, R₁ is a five- to six-membered monocyclic saturated orunsaturated non-aromatic ring system, wherein said ring system maycontain from 1 to 4 hetero atoms selected from nitrogen, oxygen andsulfur, and wherein said ring system may be substituted once or morethan once by R₆; each R₆ independently is halogen, hydroxyl, amino,cyano, nitro, C₁₋₄alkyl, C₁₋₄alkoxy or C₃₋₆cycloalkyl;

R₂ is C₂₋₆alkyl which may be substituted once or more than once by R₇;

or R₂ is —X₁—R₈; —X₁— is —O—, —S— or —N(R₉)—; R₉ is hydrogen orC₁₋₄alkyl; and R₈ is C₁₋₆alkyl which may be substituted once or morethan once by R₁₀; each R₁₀ independently is halogen, hydroxyl, amino,cyano, nitro, C₁₋₄alkoxy or C₃₋₆cycloalkyl;or R₂ is a three- to five-membered monocyclic saturated or unsaturatednon-aromatic ring system, wherein said ring system may contain from 1 to4 hetero atoms selected from nitrogen, oxygen and sulfur, and whereinsaid ring system may be substituted once or more than once by R₁₁; eachR₁₁ independently is halogen, hydroxyl, amino, cyano, nitro, C₁₋₄alkyl,C₁₋₄alkoxy or C₃₋₆cycloalkyl;

R₃ is —CH₂R₁₈; and R₁₈ is hydrogen;

R₄ and R₅ are both hydrogen.

Further examples of suitable compounds of the invention are compoundsselected from the following group P:

Group P: Suitable Compounds of the Invention:

-   2-cyclobutyl-10-methyl-3-phenylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione;-   10-allyl-2-isopropyl-3-phenylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione;-   2-isopropyl-3-phenylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione;-   10-allyl-2-cyclobutyl-3-phenylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione;-   2-cyclobutyl-3-phenylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione;-   10-methyl-2-(3-methylcyclobutyl)-3-phenylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione;-   2-(3,3-dimethylcyclobutyl)-10-methyl-3-phenylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione;-   2-(3-methoxycyclobutyl)-10-methyl-3-phenylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione;-   10-methyl-2-(pentan-3-yl)-3-phenylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione;-   2-cyclopentyl-10-methyl-3-phenylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione;-   2-cyclopropyl-10-methyl-3-phenylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione;-   2-butyl-10-methyl-3-phenylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione;-   2-(3-methoxypropyl)-10-methyl-3-phenylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione;-   2-(4-methoxybutyl)-10-methyl-3-phenylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione;-   3-(2-fluorophenyl)-2-isopropyl-10-methylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione;-   3-(2-chlorophenyl)-2-isopropyl-10-methylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione;-   3-(2,6-dichlorophenyl)-2-isopropyl-10-methylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione;-   2-isopropyl-10-methyl-3-(o-tolyl)pyrimido[4,5-b]quinoline-4,5(3H,10H)-dione;-   2-isopropyl-3-(2-methoxyphenyl)-10-methylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione;-   2-isopropyl-10-methyl-3-(2-(trifluoromethyl)phenyl)pyrimido[4,5-b]quinoline-4,5(3H,10H)-dione;-   3-(3-chlorophenyl)-2-isopropyl-10-methylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione;-   2-isopropyl-3-(3-methoxyphenyl)-10-methylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione;-   7-fluoro-2-isopropyl-10-methyl-3-phenylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione;-   7-chloro-2-isopropyl-10-methyl-3-phenylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione;-   7-bromo-2-isopropyl-10-methyl-3-phenylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione;-   2-isopropyl-7,10-dimethyl-3-phenylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione;-   9-isopropyl-8-phenyl-1H-pyrimido[4,5-b]pyrrolo[3,2,1-ij]quinoline-6,7(2H,8H)-dione;-   2-isopropyl-10-methyl-3-phenylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione;-   10-methyl-2-pentyl-3-phenylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione;-   10-methyl-3-phenyl-2-propylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione;-   2-ethyl-10-methyl-3-phenylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione;-   2-cyclohexyl-10-methyl-3-phenylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione;-   3-(3,5-dimethylphenyl)-2-ethyl-10-methylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione;-   3-(3,5-dimethylphenyl)-10-methyl-2-pentylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione;-   3-(3,5-dimethylphenyl)-2-isopropyl-10-methylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione;-   3-(3,5-dimethylphenyl)-10-methyl-2-propylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione;-   10-(2-aminoethyl)-2-cyclobutyl-3-phenylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione;-   2-isopropyl-3-(2-isopropylphenyl)-10-methylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione;-   2-cyclobutyl-10-(2-hydroxyethyl)-3-phenylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione;-   3-(2-bromophenyl)-2-isopropyl-10-methylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione;-   10-(2-aminoethyl)-2-isopropyl-3-phenylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione;-   10-(2-hydroxyethyl)-2-isopropyl-3-phenylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione;-   2-isopropyl-10-(2-methoxyethyl)-3-phenylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione;-   2-isopropyl-3-phenyl-10-propylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione;-   2-isopropyl-10-methyl-3-(tetrahydro-2H-pyran-3-yl)pyrimido[4,    5-b]quinoline-4,5(3H,10H)-dione;-   2-cyclobutyl-3-(2,6-dichlorophenyl)-10-methylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione;-   2-hexyl-10-methyl-3-phenylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione;-   2-heptyl-10-methyl-3-phenylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione;-   10-allyl-3-cyclopentyl-2-isopropylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione;-   3-cyclopentyl-2-isopropylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione;-   3-cyclopentyl-10-ethyl-2-isopropylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione;-   2-(sec-butyl)-3-cyclopentyl-10-methylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione;-   3-cyclopentyl-2-isobutyl-10-methylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione;-   2-(tert-butyl)-3-cyclopentyl-10-methylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione;-   2-isopropyl-10-methyl-3-(tetrahydro-2H-pyran-4-yl)pyrimido[4,5-b]quinoline-4,5(3H,10H)-dione;-   2-isopropyl-10-methyl-3-(piperidin-1-yl)pyrimido[4,5-b]quinoline-4,5(3H,10H)-dione;-   3-cyclopentyl-2-isopropyl-9-methoxy-10-methylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione;-   3-cyclopentyl-2-isopropyl-7-methoxy-10-methylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione;-   7-chloro-3-cyclopentyl-2-isopropyl-10-methylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione;-   7-bromo-3-cyclopentyl-2-isopropyl-10-methylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione;-   3-cyclopentyl-7-ethynyl-2-isopropyl-10-methylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione;-   3-cyclopentyl-2-isopropyl-10-methyl-4,5-dioxo-3,4,5,10-tetrahydropyrimido[4,5-b]quinoline-7-carbonitrile;-   3-cyclopentyl-2-isopropyl-10-methylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione;-   3-cyclohexyl-10-methyl-2-phenylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione;-   3-cyclohexyl-10-methyl-2-(thiophen-2-yl)pyrimido[4,5-b]quinoline-4,5(3H,10    OH)-dione;-   3-cyclopentyl-10-methyl-2-pentylpyrimido[4,5-b]quinoline-4,5(3H,10    OH)-dione;-   3-cyclohexyl-10-methyl-2-(3-nitrophenyl)pyrimido[4,5-b]quinoline-4,5(3H,10    OH)-dione;-   3-cyclohexyl-2-(furan-2-yl)-10-methylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione;-   3-cyclopentyl-10-methyl-2-propylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione;-   3-cycloheptyl-10-methyl-2-(thiophen-2-yl)pyrimido[4,5-b]quinoline-4,5(3H,10H)-dione;-   3-cycloheptyl-10-methyl-2-propylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione;-   3-cyclohexyl-10-methyl-2-propylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione;-   3-cycloheptyl-10-methyl-2-pentylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione;-   3-cycloheptyl-10-methyl-2-phenylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione;-   3-cyclohexyl-2-(4-methoxyphenyl)-10-methylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione;-   2-cyclohexyl-3-cyclopentyl-10-methylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione;-   3-cyclohexyl-2-isopropyl-10-methylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione;-   2-(3-bromophenyl)-3-cyclohexyl-10-methylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione;-   3-cycloheptyl-2-ethyl-10-methylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione;-   3-cyclopentyl-2-(2-fluorophenyl)-10-methylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione;-   3-cyclopentyl-2-(4-fluorophenyl)-10-methylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione;-   3-cyclopentyl-10-methyl-2-(o-tolyl)pyrimido[4,5-b]quinoline-4,5(3H,10H)-dione;-   2-(2-chlorophenyl)-3-cyclopentyl-10-methylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione;-   3-cyclohexyl-10-methyl-2-(p-tolyl)pyrimido[4,5-b]quinoline-4,5(3H,10H)-dione;-   3-cyclohexyl-10-methyl-2-(o-tolyl)pyrimido[4,5-b]quinoline-4,5(3H,10H)-dione;-   2-(2-chlorophenyl)-3-cyclohexyl-10-methylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione;-   3-cyclopentyl-10-methyl-2-phenylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione;-   3-cyclopentyl-10-methyl-2-(p-tolyl)pyrimido[4,5-b]quinoline-4,5(3H,10H)-dione;-   3-cyclohexyl-2-(2-fluorophenyl)-10-methylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione;-   3-cycloheptyl-10-methyl-2-(3,4,5-trimethoxyphenyl)pyrimido[4,5-b]quinoline-4,5(3H,10H)-dione;-   3-cyclopentyl-10-methyl-2-(thiophen-2-yl)pyrimido[4,5-b]quinoline-4,5(3H,10H)-dione;-   2-(4-chlorophenyl)-3-cyclohexyl-10-methylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione;-   3-cyclohexyl-10-methyl-2-(4-nitrophenyl)pyrimido[4,5-b]quinoline-4,5(3H,10H)-dione;-   3-cycloheptyl-10-methyl-2-(3-nitrophenyl)pyrimido[4,5-b]quinoline-4,5(3H,10H)-dione;-   3-cycloheptyl-2-(4-methoxyphenyl)-10-methylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione;-   3-cycloheptyl-10-methyl-2-(o-tolyl)pyrimido[4,5-b]quinoline-4,5(3H,10H)-dione;-   3-cyclopentyl-2-(furan-2-yl)-10-methylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione;-   2-(3-bromophenyl)-3-cycloheptyl-10-methylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione;-   9-chloro-3-cyclopentyl-2-isopropyl-10-methylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione;    or-   2-(ethylthio)-3-phenylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione;-   2-(dimethylamino)-3-phenylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione;    or-   2-(dimethylamino)-10-methyl-3-phenylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione;    or salts of these compounds.

Further examples of suitable compounds of the invention are compoundsselected from the following group Q:

Group Q: Suitable Compounds of the Invention:

-   2-cyclobutyl-10-methyl-3-phenylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione;-   10-allyl-2-isopropyl-3-phenylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione;-   2-isopropyl-3-phenylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione;-   10-allyl-2-cyclobutyl-3-phenylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione;-   2-cyclobutyl-3-phenylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione;-   10-methyl-2-(3-methylcyclobutyl)-3-phenylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione;-   2-(3,3-dimethylcyclobutyl)-10-methyl-3-phenylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione;-   2-(3-methoxycyclobutyl)-10-methyl-3-phenylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione;-   10-methyl-2-(pentan-3-yl)-3-phenylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione;-   2-cyclopentyl-10-methyl-3-phenylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione;-   2-cyclopropyl-10-methyl-3-phenylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione;-   2-butyl-10-methyl-3-phenylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione;-   2-(3-methoxypropyl)-10-methyl-3-phenylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione;-   2-(4-methoxybutyl)-10-methyl-3-phenylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione;-   3-(2-fluorophenyl)-2-isopropyl-10-methylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione;-   3-(2-chlorophenyl)-2-isopropyl-10-methylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione;-   3-(2,6-dichlorophenyl)-2-isopropyl-10-methylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione;-   2-isopropyl-10-methyl-3-(o-tolyl)pyrimido[4,5-b]quinoline-4,5(3H,10H)-dione;-   2-isopropyl-3-(2-methoxyphenyl)-10-methylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione;-   2-isopropyl-10-methyl-3-(2-(trifluoromethyl)phenyl)pyrimido[4,5-b]quinoline-4,5(3H,10    OH)-dione;-   3-(3-chlorophenyl)-2-isopropyl-10-methylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione;-   2-isopropyl-3-(3-methoxyphenyl)-10-methylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione;-   7-fluoro-2-isopropyl-10-methyl-3-phenylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione;-   7-chloro-2-isopropyl-10-methyl-3-phenylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione;-   7-bromo-2-isopropyl-10-methyl-3-phenylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione;-   2-isopropyl-7,10-dimethyl-3-phenylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione;-   9-isopropyl-8-phenyl-1H-pyrimido[4,5-b]pyrrolo[3,2,1-ij]quinoline-6,7(2H,8H)-dione;-   10-allyl-3-cyclopentyl-2-isopropylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione;-   3-cyclopentyl-2-isopropylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione;-   3-cyclopentyl-10-ethyl-2-isopropylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione;-   2-(sec-butyl)-3-cyclopentyl-10-methylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione;-   3-cyclopentyl-2-isobutyl-10-methylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione;-   2-(tert-butyl)-3-cyclopentyl-10-methylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione;-   2-isopropyl-10-methyl-3-(tetrahydro-2H-pyran-4-yl)pyrimido[4,5-b]quinoline-4,5(3H,10H)-dione;-   2-isopropyl-10-methyl-3-(piperidin-1-yl)pyrimido[4,5-b]quinoline-4,5(3H,10H)-dione;-   3-cyclopentyl-2-isopropyl-9-methoxy-10-methylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione;-   3-cyclopentyl-2-isopropyl-7-methoxy-10-methylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione;-   7-chloro-3-cyclopentyl-2-isopropyl-10-methylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione;-   7-bromo-3-cyclopentyl-2-isopropyl-10-methylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione;-   3-cyclopentyl-7-ethynyl-2-isopropyl-10-methylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione;-   3-cyclopentyl-2-isopropyl-10-methyl-4,5-dioxo-3,4,5,10-tetrahydropyrimido[4,5-b]quinoline-7-carbonitrile;-   9-chloro-3-cyclopentyl-2-isopropyl-10-methylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione;-   2-(ethylthio)-3-phenylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione;-   2-(dimethylamino)-3-phenylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione;    or-   2-(dimethylamino)-10-methyl-3-phenylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione;-   10-(2-aminoethyl)-2-cyclobutyl-3-phenylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione;-   2-isopropyl-3-(2-isopropylphenyl)-10-methylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione;-   2-cyclobutyl-10-(2-hydroxyethyl)-3-phenylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione;-   3-(2-bromophenyl)-2-isopropyl-10-methylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione;-   10-(2-aminoethyl)-2-isopropyl-3-phenylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione;-   10-(2-hydroxyethyl)-2-isopropyl-3-phenylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione;-   2-isopropyl-10-(2-methoxyethyl)-3-phenylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione;-   2-isopropyl-3-phenyl-10-propylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione;-   2-isopropyl-10-methyl-3-(tetrahydro-2H-pyran-3-yl)pyrimido[4,    5-b]quinoline-4,5(3H,10H)-dione;-   2-cyclobutyl-3-(2,6-dichlorophenyl)-10-methylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione;-   2-hexyl-10-methyl-3-phenylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione;-   2-heptyl-10-methyl-3-phenylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione;    or salts of these compounds.

Compounds of the formula I can be prepared by conventional processes,e.g. as described in the Examples, which processes are further aspectsof the invention. Furthermore, compounds of formula I or theirprecursors may be obtainable from compounds which are described in theExamples, e.g. by reduction, oxidation and/or other functionalization ofresulting compounds and/or by cleavage of any protecting group(s)optionally present, and of recovering the so obtainable compound of theformula I or the intended precursor. The reactions can be effectedaccording to conventional methods, for example as described in theExamples. The work-up of the reaction mixtures and the purification ofthe compounds thus obtainable may be carried out in accordance withknown procedures. Acid addition salts may be produced from the freebases in known manner, and vice-versa. Starting materials, e.g. startingmaterials as described in the Examples, may be known or preparedaccording to conventional procedures starting from known compounds.

The invention also contemplates that compounds of formula (I) may beformed by in vivo biotransformation from pro-drugs.

In another aspect, the invention provides a pharmaceutical compositioncomprising a compound of the invention and a pharmaceutically acceptablecarrier. The pharmaceutical composition can be formulated for particularroutes of administration such as oral administration, parenteraladministration, and rectal administration, etc. In addition, thepharmaceutical compositions of the invention can be made up in a solidform including capsules, tablets, pills, granules, powders orsuppositories, or in a liquid form including solutions, suspensions oremulsions. The pharmaceutical compositions can be subjected toconventional pharmaceutical operations such as sterilization and/or cancontain conventional inert diluents, lubricating agents, or bufferingagents, as well as adjuvants, such as preservatives, stabilizers,wetting agents, emulsifiers and buffers etc.

Typically, the pharmaceutical compositions are tablets and gelatincapsules comprising the active ingredient together with

-   -   a) diluents, e.g., lactose, dextrose, sucrose, mannitol,        sorbitol, cellulose and/or glycine;    -   b) lubricants, e.g., silica, talcum, stearic acid, its magnesium        or calcium salt and/or polyethyleneglycol; for tablets also    -   c) binders, e.g., magnesium aluminum silicate, starch paste,        gelatin, tragacanth, methylcellulose, sodium        carboxymethylcellulose and/or polyvinylpyrrolidone; if desired    -   d) disintegrants, e.g., starches, agar, alginic acid or its        sodium salt, or effervescent mixtures; and/or    -   e) absorbents, colorants, flavors and sweeteners.

Tablets may be either film coated or enteric coated according to methodsknown in the art.

Suitable compositions for oral administration include an effectiveamount of a compound of the invention in the form of tablets, lozenges,aqueous or oily suspensions, dispersible powders or granules, emulsion,hard or soft capsules, or syrups or elixirs. Compositions intended fororal use are prepared according to any method known in the art for themanufacture of pharmaceutical compositions and such compositions cancontain one or more agents selected from the group consisting ofsweetening agents, flavoring agents, coloring agents and preservingagents in order to provide pharmaceutically elegant and palatablepreparations. Tablets contain the active ingredient in admixture withnontoxic pharmaceutically acceptable excipients which are suitable forthe manufacture of tablets. These excipients are, for example, inertdiluents, such as calcium carbonate, sodium carbonate, lactose, calciumphosphate or sodium phosphate; granulating and disintegrating agents,for example, corn starch, or alginic acid; binding agents, for example,starch, gelatin or acacia; and lubricating agents, for example magnesiumstearate, stearic acid or talc. The tablets are uncoated or coated byknown techniques to delay disintegration and absorption in thegastrointestinal tract and thereby provide a sustained action over alonger period. For example, a time delay material such as glycerylmonostearate or glyceryl distearate can be employed. Formulations fororal use can be presented as hard gelatin capsules wherein the activeingredient is mixed with an inert solid diluent, for example, calciumcarbonate, calcium phosphate or kaolin, or as soft gelatin capsuleswherein the active ingredient is mixed with water or an oil medium, forexample, peanut oil, liquid paraffin or olive oil.

Certain injectable compositions are aqueous isotonic solutions orsuspensions, and suppositories are advantageously prepared from fattyemulsions or suspensions. Said compositions may be sterilized and/orcontain adjuvants, such as preserving, stabilizing, wetting oremulsifying agents, solution promoters, salts for regulating the osmoticpressure and/or buffers. In addition, they may also contain othertherapeutically valuable substances.

Said compositions are prepared according to conventional mixing,granulating or coating methods, respectively, and contain about 0.1-75%,or contain about 1-50%, of the active ingredient.

Suitable compositions for transdermal application include an effectiveamount of a compound of the invention with carrier. Carriers includeabsorbable pharmacologically acceptable solvents to assist passagethrough the skin of the host. For example, transdermal devices are inthe form of a bandage comprising a backing member, a reservoircontaining the compound optionally with carriers, optionally a ratecontrolling barrier to deliver the compound of the skin of the host at acontrolled and predetermined rate over a prolonged period of time, andmeans to secure the device to the skin.

Suitable compositions for topical application, e.g., to the skin andeyes, include aqueous solutions, suspensions, ointments, creams, gels orsprayable formulations, e.g., for delivery by aerosol or the like. Suchtopical delivery systems will in particular be appropriate for dermalapplication, e.g., for the treatment of skin cancer, e.g., forprophylactic use in sun creams, lotions, sprays and the like. They arethus particularly suited for use in topical, including cosmetic,formulations well-known in the art. Such may contain solubilizers,stabilizers, tonicity enhancing agents, buffers and preservatives.

As used herein a topical application may also pertain to an inhalationor to an intranasal application. They are conveniently delivered in theform of a dry powder (either alone, as a mixture, for example a dryblend with lactose, or a mixed component particle, for example withphospholipids) from a dry powder inhaler or an aerosol spraypresentation from a pressurised container, pump, spray, atomizer ornebuliser, with or without the use of a suitable propellant.

The invention further provides anhydrous pharmaceutical compositions anddosage forms comprising the compounds of the invention as activeingredients, since water may facilitate the degradation of certaincompounds.

Anhydrous pharmaceutical compositions and dosage forms of the inventioncan be prepared using anhydrous or low moisture containing ingredientsand low moisture or low humidity conditions. An anhydrous pharmaceuticalcomposition may be prepared and stored such that its anhydrous nature ismaintained. Accordingly, anhydrous compositions are preferably packagedusing materials known to prevent exposure to water such that they can beincluded in suitable formulary kits. Examples of suitable packaginginclude, but are not limited to, hermetically sealed foils, plastics,unit dose containers (e. g., vials), blister packs, and strip packs.

The invention further provides pharmaceutical compositions and dosageforms that comprise one or more agents that reduce the rate by which thecompound of the invention as an active ingredient will decompose. Suchagents, which are referred to herein as “stabilizers,” include, but arenot limited to, antioxidants such as ascorbic acid, pH buffers, or saltbuffers, etc.

As used herein, the term “pharmaceutically acceptable carrier” includesany and all solvents, dispersion media, coatings, surfactants,antioxidants, preservatives (e.g., antibacterial agents, antifungalagents), isotonic agents, absorption delaying agents, salts,preservatives, drugs, drug stabilizers, binders, excipients,disintegration agents, lubricants, sweetening agents, flavoring agents,dyes, such like materials and combinations thereof, as would be known toone of ordinary skill in the art (see, for example, Remington'sPharmaceutical Sciences, 18th Ed. Mack Printing Company, 1990, pp.1289-1329). Except insofar as any conventional carrier is incompatiblewith the active ingredient, its use in the therapeutic or pharmaceuticalcompositions is contemplated.

The compounds of formula I or pharmaceutical acceptable salts thereofexhibit valuable pharmacological properties and are therefore useful aspharmaceuticals.

Furthermore, compounds of formula I may be useful for research ondiseases caused by nonsense mutations, e.g. as tool compounds.

In particular, compounds of formula I act as nonsense mutationsuppressors on frequent PTCs, e.g. on Y122X in the mRNA of the cysticfibrosis conductance regulator protein (CFTR). This can be determined invitro, for example, using cell lines expressing GFP-CFTR-Y122X-Renillaconstructs as described herein.

The compounds of the invention may be therefore useful in theprevention, treatment or delay of progression of diseases caused bynonsense mutations

The term “disease caused by nonsense mutation” is known in the field. Itrelates to a disease being present in patients carrying a nonsensemutation in a disease-relevant gene wherein the nonsense mutation causesa partial/total lack of protein which then causes the pathology of thedisease.

In one embodiment, the disease is selected from hemophilia A, hemophiliaB, cystic fibrosis, mucopolysaccharidosis I, Duchenne Muscle Dystrophy,Becker Muscle Dystrophy, loss of APC caused cancer and loss of p53caused cancer.

For the above-mentioned indications (the conditions and disorders) theappropriate dosage will vary depending upon, for example, the compoundemployed, the host, the mode of administration and the nature andseverity of the condition being treated. However, in general,satisfactory results in animals are indicated to be obtained at a dailydosage of from about 0.01 to about 100 mg/kg body weight, preferablyfrom about 0.1 to about 10 mg/kg body weight, e.g. 1 mg/kg. In largermammals, for example humans, an indicated daily dosage is in the rangefrom about 0.1 to about 1000 mg, preferably from about 1 to about 400mg, most preferably from about 10 to about 100 mg of the compound of theinvention conveniently administered, for example, in divided doses up tofour times a day.

For use according to the invention, a compound of the invention,especially a compound as defined in group P, may be administered assingle active agent or in combination with other active agents, in anyusual manner, e.g. orally, for example in the form of tablets orcapsules, or parenterally, for example in the form of injectionsolutions or suspensions. A combination comprising a compound of theinvention and another active agent will be referred to as “combinationof the invention”.

A compound of the invention, especially being a compound as defined ingroup P, may be combined with a readthrough activator, e.g. negamycin,RT13, RT14, ataluren or an aminoglycoside readthrough activator, e.g.paromomycin, amikacin, G418, NB30, NB54 or NB84. An example of acombination is the first compound as defined in group P, i.e.2-cyclobutyl-10-methyl-3-phenylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione,and negamycin.

A compound of the invention, especially being a compound as defined ingroup P, may be combined with a nonsense-mediated mRNA decay inhibitor,e.g. NMDI-1. An example of a combination is the first compound asdefined in group P, i.e.2-cyclobutyl-10-methyl-3-phenylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione,and NMDI-1.

A compound of the invention, especially being a compound as defined ingroup Q, may be combined with a readthrough activator, e.g. negamycin,RT13, RT14, ataluren or an aminoglycoside readthrough activator, e.g.paromomycin, amikacin, G418, NB30, NB54 or NB84.

A compound of the invention, especially being a compound as defined ingroup Q, may be combined with a nonsense-mediated mRNA decay inhibitor,e.g. NMDI-1.

Negamycin, RT13, RT14, ataluren, aminoglycoside readthrough activatorsand NMDI-1 are described e.g. in Keeling et al, WIREs RNA, 2011, 2,837-852.

The compounds of the invention may be useful for the prevention ofdiseases caused by nonsense mutations.

The compounds of the invention may be useful for the treatment ofdiseases caused by nonsense mutations.

The compounds of the invention may be useful for the delay ofprogression of diseases caused by nonsense mutations.

In another embodiment, the invention provides a method of treating adisease caused by a nonsense mutation comprising administration of atherapeutically effective amount of a compound of formula (I) or apharmaceutically acceptable salt thereof. In a further embodiment, theinvention provides a method of treating a disease caused by a nonsensemutation comprising administration of a therapeutically effective amountof a compound of formula (I) or a pharmaceutically acceptable saltthereof, wherein the disease is selected from the afore-mentioned list,suitably hemophilia A, hemophilia B, cystic fibrosis andmucopolysaccharidosis I (Hurler syndrome).

The term “a therapeutically effective amount” of a compound of theinvention refers to an amount of the compound of the invention that willelicit the biological or medical response of a subject, for example,ameliorate symptoms, alleviate conditions, slow or delay diseaseprogression, or prevent a disease, etc. In one non-limiting embodiment,the term “a therapeutically effective amount” refers to the amount ofthe compound of the invention that, when administered to a subject, iseffective to at least partially alleviating, inhibiting, preventingand/or ameliorating a disease caused by nonsense mutations. In anothernon-limiting embodiment, the term “a therapeutically effective amount”refers to the amount of the compound of the invention that, whenadministered to a cell, or a tissue, or a non-cellular biologicalmaterial, or a medium, is effective to at least partially suppress theeffect of nonsense mutations.

As used herein, the term “subject” refers to an animal. Preferably, theanimal is a mammal.

A subject also refers to for example, primates (e.g., humans), cows,sheep, goats, horses, dogs, cats, rabbits, rats, mice, fish, birds andthe like. In a preferred embodiment, the subject is a human.

As used herein, the term “inhibition” or “inhibiting” refers to thereduction or suppression of a given condition, symptom, or disorder, ordisease, or a significant decrease in the baseline activity of abiological activity or process.

As used herein, the term “treating” or “treatment” of any disease ordisorder refers in one embodiment, to ameliorating the disease ordisorder (i.e., slowing or arresting or reducing the development of thedisease or at least one of the clinical symptoms thereof). In anotherembodiment “treating” or “treatment” refers to alleviating orameliorating at least one physical parameter including those which maynot be discernible by the patient. In yet another embodiment, “treating”or “treatment” refers to modulating the disease or disorder, eitherphysically, (e.g., stabilization of a discernible symptom),physiologically, (e.g., stabilization of a physical parameter), or both.In yet another embodiment, “treating” or “treatment” refers topreventing or delaying the onset or development or progression of thedisease or disorder.

The pharmaceutical composition or combination of the invention can be inunit dosage of about 1-1000 mg of active ingredient(s) for a subject ofabout 50-70 kg, or about 1-500 mg or about 1-250 mg or about 1-150 mg orabout 0.5-100 mg, or about 1-50 mg of active ingredients. Thetherapeutically effective dosage of a compound, the pharmaceuticalcomposition, or the combinations thereof, is dependent on the species ofthe subject, the body weight, age and individual condition, the disorderor disease or the severity thereof being treated. A physician, clinicianor veterinarian of ordinary skill can readily determine the effectiveamount of each of the active ingredients necessary to prevent, treat orinhibit the progress of the disorder or disease.

The above-cited dosage properties are demonstrable in vitro and in vivotests using advantageously mammals, e.g., mice, rats, dogs, monkeys orisolated organs, tissues and preparations thereof. The compounds of theinvention can be applied in vitro in the form of solutions, e.g.,preferably aqueous solutions, and in vivo either enterally,parenterally, advantageously intravenously, e.g., as a suspension or inaqueous solution. The dosage in vitro may range between about 10⁻³ molarand 10⁻⁹ molar concentrations. A therapeutically effective amount invivo may range depending on the route of administration, between about0.1-500 mg/kg, or between about 1-100 mg/kg.

The activity of a compound of the invention can be assessed by in vitro& in vivo methods described herein.

The compound of the invention may be administered either simultaneouslywith, or before or after, at least one other therapeutic agent. Thecompound of the invention may be administered separately, by the same ordifferent route of administration, or together in the samepharmaceutical composition.

The following Examples illustrate the invention, but do not limit it.

Experimental Part:

Abbreviations:

-   DCM dichloromethane-   DMF dimethylformamide-   DMA dimethylacetamide-   TBME tert.butylmethylether

LC-MS Method:

Waters Acquity UPLC-SQD system; mobile phase: A: water (0.05% formicacid) B: methanol (0.04% formic acid); gradient: from 2% B to 8% B in0.1 min, from 8% B to 98% B in 0.5 min, 98% B for 0.1 min; flow rate 1mL/min; column Waters Acquity UPLC BEH C18, 30×2.1 mm, 1.7 mM; oventemperature 60° C.

NMR Device:

Bruker Avance 400 MHz Ultrashield

EXAMPLES Example 1.1:2-cyclobutyl-10-methyl-3-phenylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione

a) 2-amino-1-methyl-4-oxo-N-phenyl-1,4-dihydroquinoline-3-carboxamide

2.235 g of a 60% suspension of NaH in mineral oil (55.9 mmol) wassuspended in 100 mL dry DMA and 4.48 g 2-cyanoacetanilide (27.9 mmol)were added in portions within 15 minute at 5-10° C. and stirred for 30minutes at room temperature. The mixture was cooled to 0° C. and 5 g1-methyl-1H-benzo[d][1,3]oxazine-2,4-dione (25.4 mmol) were added inportions within 5 minutes and stirred at room temperature for 60minutes. 27.9 mL aqueous hydrochloric acid (2 M, 55.9 mmol) were addedwithin 10 minutes and the mixture was heated to 50° C. for 1 hour. Thereaction mixture was cooled to room temperature, poured into 450 mL 10%aqueous potassium hydrogencarbonate solution and stirred for 30 minutes.The resulting solid was filtered, washed with water, diethylether/pentane 3:2, and pentane and dried to yield 5.0 g2-amino-1-methyl-4-oxo-N-phenyl-1,4-dihydroquinoline-3-carboxamide(16.71 mmol, 66%) as a yellow powder.

b)2-cyclobutyl-10-methyl-3-phenylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione

To a suspension of 130 mg2-amino-1-methyl-4-oxo-N-phenyl-1,4-dihydroquinoline-3-carboxamide(0.443 mmol) in 1.3 mL cyclobutyric acid (1.36 mL, 13.3 mmol) 242 mgcyclobutyric anhydride (1.33 mmol) and 129 μL propane phosphonic acidanhydride 50% in DMF (70 mg, 0.22 mmol) were added subsequently and themixture was heated to 150° C. for 90 minutes. The solution was cooled to70° C., one mL methanol added and stirred for one hour. The reactionmixture was cooled to room temperature, 5 mL diethyl ether and 1 mLpentane added and the resulting mixture was stirred for 15 minutes,filtered and the resulting solid washed with diethyl ether/pentane 3:2.The solid was dissolved in DCM and extracted with 0.1M sodium hydroxidesolution, the organic phases dried with sodium sulfate, filtered andevaporated. The resulting solid was stirred with 5 mL diethyl ether,filtered, washed with diethyl ether/pentane 3:2 and dried under vacuumto yield 135 mg2-cyclobutyl-10-methyl-3-phenylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione(0.37 mmol, 84%) as a white powder.

¹H-NMR (400 MHz, D₆-DMSO): δ(ppm)=8.23 (d, 1H, ³J=7.65 Hz), 7.89-7.80(m, 2H), 7.59-7.49 (m, 3H), 7.44 (t, 1H, ³J=7.15 Hz), 7.36 (d, 2H,³J=6.65 Hz), 4.11 (s, 3H), 3.28-3.20 (m, 1H), 2.48-2.38 (m, 2H),1.81-1.61 (m, 4H).

Example 2.1/Example 2.2:10-allyl-3-cyclopentyl-2-isopropylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione/3-cyclopentyl-2-isopropylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione

a) 1-allyl-1H-benzo[d][1,3]oxazine-2,4-dione

0.485 g of a 60% suspension of NaH in mineral oil (12.14 mmol) wassuspended in 48.2 mL dry DMA, cooled to 0° C. and 2 g1H-benzo[d][1,3]oxazine-2,4-dione (90% technical grade, 11.03 mmol) wereadded in portions and stirred for 1 hour. Then, 1.315 mL allyl iodide(2.41 g, 14.34 mmol) were slowly added and stirred at room temperaturefor 1.5 hours. The reaction mixture was poured into 250 mL 0.1 M aqueoushydrochloric acid and stirred for 10 minutes. The resulting solid wasfiltered and washed with 60 mL water and 20 mL diethyl ether/pentane(8:2) and dried under vacuum at 65° C. to yield 1.88 g1-allyl-1H-benzo[d][1,3]oxazine-2,4-dione (9.25 mmol, 84%) as anoff-white solid.

b) 2-cyano-N-cyclopentylacetamide

To 5.98 mL cyclopentylamine (5.155 g, 60.5 mmol) under an atmosphere ofnitrogen 5.32 mL methyl 2-cyanoacetate (6 g, 60.5 mmol) were addeddropwise maintaining a reaction temperature below 30° C. After 30 minthe suspension was diluted with 8 mL diethyl ether and 2 mL pentane,stirred for 40 min, filtered and the remaining solid washed with diethylether and pentane and dried to yield 4.343 g of2-cyano-N-cyclopentylacetamide (28.5 mmol, 47%) as a white solid.

c)1-allyl-2-amino-N-cyclopentyl-4-oxo-1,4-dihydroquinoline-3-carboxamide

0.39 g of a 60% suspension of NaH in mineral oil (9.74 mmol) wassuspended in 20.4 mL dry DMA and 0.742 g 2-cyano-N-cyclopentylacetamide(4.87 mmol) were added in portions and stirred for 50 minutes. Thesolution was cooled to 0° C. and 0.9 g1-allyl-1H-benzo[d][1,3]oxazine-2,4-dione (4.43 mmol) were added inportions and stirred for 50 minutes. 9.74 mL aqueous hydrochloric acid(2 M, 19.5 mmol) were added and the mixture was heated to 60° C. for 2hours. The reaction mixture was cooled to room temperature, poured into10% aqueous potassium hydrogen carbonate solution and stirred for 10min. The resulting solid was filtered, washed with water and diethylether and dried to yield 1.2 g1-allyl-2-amino-N-cyclopentyl-4-oxo-1,4-dihydroquinoline-3-carboxamide(4.13 mmol, 94%) as an off-white solid.

d)10-allyl-3-cyclopentyl-2-isopropylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione

To a suspension of 396 mg1-allyl-2-amino-N-cyclopentyl-4-oxo-1,4-dihydroquinoline-3-carboxamide(1.273 mmol) in 4.733 mL isobutyric acid (4.487 g, 50.9 mmol) 0.844 mLisobutyric acid anhydride (0.806 g, 5.09 mmol) and 0.186 mL of a 50%solution of propane phosphonic acid anhydride in DMF (0.203 g, 0.637mmol) were added subsequently and the mixture was heated to 150° C. for5.5 h. The solution was cooled to 70° C., 1 mL methanol added, stirredfor 15 min and cooled to room temperature. 15 mL diethyl ether and 5 mLpentane were added, stirred for 5 min and another 5 mL pentane was addedto the suspension and stirred for another 15 min. The mixture wasfiltered, the solid washed with diethyl ether/pentane 3:2 and dried toyield 0.398 g10-allyl-3-cyclopentyl-2-isopropylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione(1.095 mmol, 86%) as an off-white solid.

¹H-NMR (400 MHz, D₆-DMSO): δ(ppm)=8.22 (dd, 1H, ³J=8.0 Hz ⁴J=1.5 Hz),7.78-7.68 (m, 2H), 7.41-7.36 (m, 1H), 6.12-6.00 (m, 1H), 5.30 (bs, 2H),5.19 (dd, 1H, ³J=10.6 Hz ⁴J=1.5 Hz), 5.09 (dd, 1H, ³J=17.1 Hz 4J=1.5Hz), 4.89 (quint, 1H, ³J=8.3 Hz), 3.45 (sept, 1H, ³J=6.4 Hz), 2.22-2.12(m, 2H), 2.06-1.95 (m, 2H), 1.95-1.85 (m, 2H), 1.68-1.57 (m, 2H), 1.30(d, 6H,6.8 Hz).

e) 3-cyclopentyl-2-isopropylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione

To 51 mg10-allyl-3-cyclopentyl-2-isopropylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione(0.14 mmol) and 11.3 mg tetrakis(triphenylphosphine)-palladium(0) (0.01mmol) in 3.5 mL DCM 25 mg p-toluene sulfinic acid (0.16 mmol) were addedunder an atmosphere of argon and stirred at room temperature for 93 h.Another 4.8 mg tetrakis(triphenylphosphine)-palladium(0) (0.004 mmol)and 11 mg p-toluene sulfinic acid (0.07 mmol) were added and stirred foranother 97 h. The solution was diluted with 30 mL ethyl acetate/TBME 1:1and extracted twice with 10 mL 1M aqueous sodium carbonate solution. Theaqueous phases were extracted with 30 mL ethyl acetate/TBME 1:1 and 30mL TBME. Combined organic layers were dried over sodium sulfate,filtered and evaporated to dryness. The resulting oil was purified bySFC and target fractions were evaporated to yield 10.4 mg3-cyclopentyl-2-isopropylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione(0.032 mmol, 23%) as an off-white solid.

¹H-NMR (400 MHz, D₆-DMSO): δ(ppm)=11.93 (bs, 1H), 8.08 (dd, 1H, ³J=8.3Hz ⁴J=1.5 Hz), 7.66 (dt, 1H, ³J=7.9 Hz ⁴J=1.5 Hz), 7.59 (d, 1H, ³J=7.4),7.29 (dt, 1H, ³J=7.3 ⁴J=1.0 Hz), 4.87 (quint, 1H, ³J=8.3), 3.41 (quint,1H, ³J=6.9), 2.20-2.11 (m, 2H), 2.05-1.94 (m, 2H), 1.94-1.83 (m, 2H),1.67-1.57 (m, 2H), 1.31 (d, 6H, ³J=6.8).

Example 3.1/Example 3.2:2-(ethylthio)-3-phenylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione/2-(dimethylamino)-3-phenylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione

a) 2-(ethylthio)-6-hydroxy-3-phenylpyrimidin-4(3H)-one

27.5 mL 1M sodium methylate in methanol (1.49 g, 27.5 mmol) were addedat room temperature to a solution of 1.56 mL dimethyl malonate (1.8 g,13.1 mmol) in 20 mL methanol and stirred for 30 minutes. To thissolution 1.6 g phenylthiourea (10.5 mmol) were added in portions,stirred at room temperature for 15 minutes and then refluxed for 3.5 h.Heating was removed and 1.06 mL ethyliodide (13.1 mmol) were added at50° C., stirred for another 30 minutes and then at room temperature overnight. Then 1.57 mL acetic acid were added, stirred 5 minutes and 190 mLwater were slowly added with stirring. The resulting suspension wasstirred for another 30 minutes, filtered, washed with water and pentaneand dried under vacuum at 75° C. to yield 2.33 g2-(ethylthio)-6-hydroxy-3-phenylpyrimidin-4(3H)-one (9.4 mmol, 90%) as awhite solid.

b) 6-chloro-2-(ethylthio)-3-phenylpyrimidin-4(3H)-one

To a suspension of 519 mg2-(ethylthio)-6-hydroxy-3-phenylpyrimidin-4(3H)-one (2.09 mmol) and0.264 mL N,N-dimethylaniline (253 mg, 2.09 mmol) 0.86 mLphosphoroxychloride (1.44 g, 9.4 mmol) were added at room temperatureand the resulting solution was stirred for 10 minutes and then stirredat 95° C. for 35 minutes. The mixture was evaporated, hydrolyzed with 20mL cold water, extracted with dichloromethane, the combined organicphases dried with sodiumsulfate, and evaporated. The resulting red oilwas suspended in 1 mL diethyl ether, 1 g silica gel added, stirred for10 minutes, filtered over Hyflo, washed with diethyl ether andevaporated. 10 mL pentane was added and the resulting solid wasfiltered, washed with pentane and dried to result 376 mg6-chloro-2-(ethylthio)-3-phenylpyrimidin-4(3H)-one (1.48 mmol, 71%) asan off-white solid.

c)2-((2-(ethylthio)-6-oxo-1-phenyl-1,6-dihydropyrimidin-4-yl)amino)benzoicacid

To a solution of 969 mg6-chloro-2-(ethylthio)-3-phenylpyrimidin-4(3H)-one (3.63 mmol) and 0.94mL methyl anthranilate (1.1 g, 7.27 mmol) in 18 mL DMA under Argon, 1 gpotassium carbonate (7.27 mmol), 136 mg BINAP (0.22 mmol) and 67 mgPd2(dba)3 (0.072 mmol) were added at room temperature and stirred at100° C. for 17 h. Another 33 mg Pd2(dba)3 (0.036 mmol) were added andstirred for 5 h at 100° C. 4.5 mL water were added to the mixture andstirred for 3.25 h at 105° C. To the cooled reaction mixture 180 mLwater and 100 mL TBME were added, the aqueous phase extracted twice withTBME, combined organic phases washed with water, combined aqueous phasesfiltered over Hyflo, neutralized with 0.83 mL acetic acid, extractedthree times with 100 mL DCM, combined DCM phases dried over sodiumsulfate, filtered and evaporated. The resulting solid was stirred with20 mL ethyl acetate, 20 mL pentane added, filtered, the solid washedwith ethyl acetate/pentane 1:1 and pentane and dried to yield 474 mg2-((2-(ethylthio)-6-oxo-1-phenyl-1,6-dihydropyrimidin-4-yl)amino)benzoicacid (1.29 mmol, 36%) as light yellow solid.

d) 2-(ethylthio)-3-phenylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione

369 mg2-((2-(ethylthio)-6-oxo-1-phenyl-1,6-dihydropyrimidin-4-yl)amino)benzoicacid (1 mmol) were stirred in 12 g polyphosphoric acid at 110° C. for 45min, cooled to room temperature and poured on 40 g ice. The resultingsolid was filtered, washed with water, 20% aqueous potassium bicarbonatesolution, water, and dried under vacuum at 50° C. for two days to yield344 mg 2-(ethylthio)-3-phenylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione(0.99 mmol, 99%) as light yellow solid.

¹H-NMR (400 MHz, D₆-DMSO): δ(ppm)=12.1 (bs, 1H), 8.08 (d, 1H, ³J=8.0Hz), 7.73-7.50 (m, 5H), 7.42-7.30 (m, 3H), 3.17 (q, 2H, ³J=7.3 Hz), 1.31(t, 3H, ³J=7.3 Hz).

e) 2-(dimethylamino)-3-phenylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione

30 mg 2-(ethylthio)-3-phenylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione(0.086 mmol) were added to 1 mL dimethylamino 33% in ethanol (333 mg,7.39 mmol) in a sealed vial and heated to 90° C. for 18 h and to 110° C.for additional 3 h. The mixture was evaporated, fractionated by RP-HPLC(C18, water/CAN 0.1% TFA), target fractions were pooled and freeze-driedto yield 12 mg2-(dimethylamino)-3-phenylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione(0.028 mmol, 33%) as a white powder.

¹H-NMR (400 MHz, D₆-DMSO): δ(ppm)=11.7 (bs, 1H), 8.02 (d, 1H, ³J=8.1Hz), 7.64-7.33 (m, 7H), 7.24 (t, 1H, ³J=7.5 Hz), 2.71 (s, 6H).

TABLE 1 Compounds of Formula (I) Examples (Ex) 1.1-1.48, 2.1-2.50 and3.1-3.3 were synthesized according to/in analogy to Examples 1.1, 2.1and 3.1 above. Examples 1.37, 1.39, 1.41 and 1.42 were prepared viaalkylation of examples 1.3 or 1.5 with 2-iodoethanol ortert-butyl(2-bromoethyl) carbamate followed by deprotection,respectively. LCMS: LCMS Rt [min], method: method A, above. LCMS Rt[min], Ex Structure Name meth. A [M + H]⁺ 1.1

2-cyclobutyl-10-methyl-3- phenylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione 0.64 358.1 1.2

10-allyl-2-isopropyl-3- phenylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione 0.64 372.0 1.3

2-isopropyl-3- phenylpyrimido[4,5-b]quinoline- 4,5(3H,10H)-dione 0.62332.1 1.4

10-allyl-2-cyclobutyl-3- phenylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione 0.66 384.1 1.5

2-cyclobutyl-3- phenylpyrimido[4,5-b]quinoline- 4,5(3H,10H)-dione 0.63344.1 1.6

10-methyl-2-(3- methylcyclobutyl)-3- phenylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione 0.65 372.1 1.7

2-(3,3-dimethylcyclobutyl)-10- methyl-3-phenylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione 0.66 386.1 1.8

2-(3-methoxycyclobutyl)-10- methyl-3-phenylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione 0.61 388.1 1.9

10-methyl-2-(pentan-3-yl)-3- phenylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione 0.66 374.1 1.10

2-cyclopentyl-10-methyl-3- phenylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione 0.65 372.1 1.11

2-cyclopropyl-10-methyl-3- phenylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione 0.62 344.1 1.12

2-butyl-10-methyl-3- phenylpyrimido[4(5-b]quinoline- 4,5(3H,10H)-dione0.64 360.1 1.13

2-(3-methoxypropyl)-10-methyl- 3-phenylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione 0.60 376.1 1.14

2-(4-methoxybutyl)-10-methyl-3- phenylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione 0.62 390.1 1.15

3-(2-fluorophenyl)-2-isopropyl- 10-methylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione 0.64 364.1 1.16

3-(2-chlorophenyl)-2-isopropyl- 10-methylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione 0.64 380.1 1.17

3-(2,6-dichlorophenyl)-2- isopropyl-10- methylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione 0.66 414.0 1.18

2-isopropyl-10-methyl-3-(o- tolyl)pyrimido[4,5-b]quinoline-4,5(3H,10H)-dione 0.64 360.1 1.19

2-isopropyl-3-(2- methoxyphenyl)-10- methylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione 0.64 376.1 1.20

2-isopropyl-10-methyl-3-(2- (trifluoromethyl)phenyl)pyrimido[4,5-b]quinoline-4,5(3H,10H)- dione 0.65 414.1 1.21

3-(3-chlorophenyl)-2-isopropyl- 10-methylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione 0.64 380.0 1.22

2-isopropyl-3-(3- methoxyphenyl)-10- methylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione 0.64 376.1 1.23

7-fluoro-2-isopropyl-10-methyl- 3-phenylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione 0.64 364.1 1.24

7-chloro-2-isopropyl-10-methyl- 3-phenylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione 0.65 380.1 1.25

7-bromo-2-isopropyl-10-methyl- 3-phenylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione 0.66 424.0 1.26

2-isopropyl-7,10-dimethyl-3- phenylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione 0.65 360.1 1.27

9-isopropyl-8-phenyl-1H- pyrimido[4,5-b]pyrrolo[3,2,1-ij]quinoline-6,7(2H,8H)-dione 0.64 358.1 1.28

2-isopropyl-10-methyl-3- phenylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione 0.63 346.1 1.29

10-methyl-2-pentyl-3- phenylpyrimido[4,5-b]quinoline- 4,5(3H,10H)-dione0.67 374.1 1.30

10-methyl-3-phenyl-2- propylpyrimido[4,5-b]quinoline- 4,5(3H,10H)-dione0.65 346.1 1.31

2-ethyl-10-methyl-3- phenylpyrimido[4,5-b]quinoline- 4,5(3H,10H)-dione0.62 332.0 1.32

2-cyclohexyl-10-methyl-3- phenylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione 0.70 386.1 1.33

3-(3,5-dimethylphenyl)-2-ethyl- 10-methylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione 0.64 360.1 1.34

3-(3,5-dimethylphenyl)-10- methyl-2-pentylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione 0.73 402.1 1.35

3-(3,5-dimethylphenyl)-2- isopropyl-10- methylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione 0.67 374.1 1.36

3-(3,5-dimethylphenyl)-10- methyl-2-propylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione 0.70 374.2 1.37

10-(2-aminoethyl)-2-cyclobutyl- 3-phenylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione 0.45 387.1 1.38

2-isopropyl-3-(2- isopropylphenyl)-10- methylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione 0.66 388.1 1.39

2-cyclobutyl-10-(2- hydroxyethyl)-3- phenylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione 0.60 388.1 1.40

3-(2-bromophenyl)-2-isopropyl- 10-methylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione 0.64 424.0 1.41

10-(2-aminoethyl)-2-isopropyl-3- phenylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione 0.44 375.1 1.42

10-(2-hydroxyethyl)-2-isopropyl- 3-phenylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione 0.59 376.1 1.43

2-isopropyl-10-(2-methoxyethyl)- 3-phenylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione 0.64 390.0 1.44

2-isopropyl-3-phenyl-10- propylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione 0.66 374.0 1.45

2-isopropyl-10-methyl-3- (tetrahydro-2H-pyran-3-yl)pyrimido[4,5-b]quinoline- 4,5(3H,10H)-dione 0.62 354.0 1.46

2-cyclobutyl-3-(2,6- dichlorophenyl)-10- methylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione 0.67 426.1 1.47

2-hexyl-10-methyl-3- phenylpyrimido[4,5-b]quinoline- 4,5(3H,10H)-dione0.67 388.1 1.48

2-heptyl-10-methyl-3- phenylpyrimido[4,5-b]quinoline- 4,5(3H,10H)-dione0.68 402.1 2.1

10-allyl-3-cyclopentyl-2- isopropylpyrimido[4,5- b]quinoline-4,5(3H,10H)-dione 0.67 364.1 2.2

3-cyclopentyl-2- isopropylpyrimido[4,5- b]quinoline-4,5(3H,10H)-dione0.63 324.1 2.3

3-cyclopentyl-10-ethyl-2- isopropylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione 0.68 352.1 2.4

2-(sec-butyl)-3-cyclopentyl-10- methylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione 0.68 352.1 2.5

3-cyclopentyl-2-isobutyl-10- methylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione 0.67 352.1 2.6

2-(tert-butyl)-3-cyclopentyl-10- methylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione 0.67 352.1 2.7

2-isopropyl-10-methyl-3- (tetrahydro-2H-pyran-4-yl)pyrimido[4,5-b]quinoline- 4,5(3H,10H)-dione 0.61 354.1 2.8

2-isopropyl-10-methyl-3- (piperidin-1-yl)pyrimido[4,5-b]quinoline-4,5(3H,10H)-dione 0.67 353.2 2.9

3-cyclopentyl-2-isopropyl-9- methoxy-10-methylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione 0.68 368.1 2.10

3-cyclopentyl-2-isopropyl-7- methoxy-10-methylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione 0.66 368.0 2.11

7-chloro-3-cyclopentyl-2- isopropyl-10- methylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione 0.68 372.0 2.12

7-bromo-3-cyclopentyl-2- isopropyl-10- methylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione 2.13

3-cyclopentyl-7-ethynyl-2- isopropyl-10- methylpyrimido[4,5-b]quinoline4,5(3H,10H)-dione 0.66 362.1 2.14

3-cyclopentyl-2-isopropyl-10- methyl-4,5-dioxo-3,4,5,10-tetrahydropyrimido[4,5- b]quinoline-7-carbonitrile 0.64 363.2 2.15

3-cyclopentyl-2-isopropyl-10- methylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione 0.65 338.1 2.16

3-cyclohexyl-10-methyl-2- phenylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione 0.69 386.1 2.17

3-cyclohexyl-10-methyl-2- (thiophen-2-yl)pyrimido[4,5-b]quinoline-4,5(3H,10H)-dione 0.69 392.1 2.18

3-cyclopentyl-10-methyl-2- pentylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione 0.68 366.1 2.19

3-cyclohexyl-10-methyl-2-(3- nitrophenyl)pyrimido[4,5-b]quinoline-4,5(3H,10H)-dione 0.67 431.1 2.20

3-cyclohexyl-2-(furan-2-yl)-10- methylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione 0.67 376.1 2.21

3-cyclopentyl-10-methyl-2- propylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione 0.67 338.2 2.22

3-cycloheptyl-10-methyl-2- (thiophen-2-yl)pyrimido[4,5-b]quinoline-4,5(3H,10H)-dione 0.69 406.1 2.23

3-cycloheptyl-10-methyl-2- propylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione 0.70 366.2 2.24

3-cyclohexyl-10-methyl-2- propylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione 0.67 352.1 2.25

3-cycloheptyl-10-methyl-2- pentylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione 0.73 394.2 2.26

3-cycloheptyl-10-methyl-2- phenylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione 0.69 400.1 2.27

3-cyclohexyl-2-(4- methoxyphenyl)-10- methylpyrimido[4,5-b]quinoline4,5(3H,10H)-dione 0.69 416.1 2.28

2-cyclohexyl-3-cyclopentyl-10- methylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione 0.68 378.1 2.29

3-cyclohexyl-2-isopropyl-10- methylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione 0.69 352.1 2.30

2-(3-bromophenyl)-3-cyclohexyl- 10-methylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione 0.73 464.1 2.31

3-cycloheptyl-2-ethyl-10- methylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione 0.68 352.1 2.32

3-cyclopentyl-2-(2-fluorophenyl)- 10-methylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione 0.65 390.1 2.33

3-cyclopentyl-2-(4-fluorophenyl)- 10-methylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione 0.65 390.0 2.34

3-cyclopentyl-10-methyl-2-(o- tolyl)pyrimido[4,5-b]quinoline-4,5(3H,10H)-dione 0.66 386.2 2.35

2-(2-chlorophenyl)-3- cyclopentyl-10- methylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione 0.67 406.1 2.36

3-cyclohexyl-10-methyl-2-(p- tolyl)pyrimido[4,5-b]quinoline-4,5(3H,10H)-dione 0.71 400.1 2.37

3-cyclohexyl-10-methyl-2-(o- tolyl)pyrimido[4,5-b]quinoline-4,5(3H,10H)-dione 0.68 400.1 2.38

2-(2-chlorophenyl)-3-cyclohexyl- 10-methylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione 0.67 420.0 2.39

3-cyclopentyl-10-methyl-2- phenylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione 0.67 372.1 2.40

3-cyclopentyl-10-methyl-2-(p- tolyl)pyrimido[4,5-b]quinoline-4,5(3H,10H)-dione 0.71 386.1 2.41

3-cyclohexyl-2-(2-fluorophenyl)- 10-methylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione 0.70 404.2 2.42

3-cycloheptyl-10-methyl-2- (3,4,5- trimethoxyphenyl)pyrimido[4,5-b]quinoline-4,5(3H,10H)-dione 0.69 490.2 2.43

3-cyclopentyl-10-methyl-2- (thiophen-2-yl)pyrimido[4,5-b]quinoline-4,5(3H,10H)-dione 0.65 378.0 2.44

2-(4-chlorophenyl)-3-cyclohexyl- 10-methylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione 0.70 420.1 2.45

3-cyclohexyl-10-methyl-2-(4- nitrophenyl)pyrimido[4,5-b]quinoline-4,5(3H,10H)-dione 0.68 431.1 2.46

3-cycloheptyl-10-methyl-2-(3- nitrophenyl)pyrimido[4,5-b]quinoline-4,5(3H,10H)-dione 0.74 445.1 2.47

3-cycloheptyl-2-(4- methoxyphenyl)-10- methylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione 0.71 430.2 2.48

3-cycloheptyl-10-methyl-2-(o- tolyl)pyrimido[4,5-b]quinoline-4,5(3H,10H)-dione 0.72 414.2 2.49

3-cyclopentyl-2-(furan-2-yl)-10- methylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione 0.64 362.1 2.50

2-(3-bromophenyl)-3- cycloheptyl-10- methylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione 0.74 478.1 2.51

9-chloro-3-cyclopentyl-2- isopropyl-10- methylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione 0.69 372.0 3.1

2-(ethylthio)-3- phenylpyrimido[4,5-b]quinoline- 4,5(3H,10H)-dione 0.61350.0 3.2

2-(dimethylamino)-3- phenylpyrimido[4,5-b]quinoline- 4,5(3H,10H)-dione0.58 333.0 3.3

2-(dimethylamino)-10-methyl-3- phenylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione 0.59 347.0

Biological Testing

1.1 In-Vitro Testing: CFTR-Y122X Assay

Activity of compounds of the present invention was examined inrecombinant, dual reporter isogenic Hek293 cell lines (“CFTR-Y122Xassay”). The engineered reporter constructs contained the 18 bp sequencestretch corresponding to a common Y122X PTC mutation in CFTR class Imutant patients (see Sermet-Gaudelus, BMC Medicine, 2007, 5(5)). Insteadof a tyrosine (Y) in position 122 of the CFTR protein a TGA stop codoninterrupts the open reading frame (Y122X) of the corresponding mRNA.This TGA stop codon triplet (followed by the pyrimidine base cytosine)is permissive to aminoglycoside mediated translational readthrough whichserved as positive control for high throughput screening. Acorresponding TAA stop codon variant and a wildtype non mutatedconstruct was used for confirmation and counter screening. The CFTRsequence was sandwiched between an eGFP reporter, and a triple myc tagsequence fused to a full length Renilla reporter. All sequences,including an intron containing one positioned pre-eGFP (b-globin intron)were cloned in frame. The corresponding expression constructs werestably expressed in the isogenic HEK-R4 cell host (Invitrogen Incorp.)and selected by blasticidin resistance. The isogenic integration of theconstruct minimizes gene dose effects and improves assayreproducibility. Stably integrated single cell derived clones wereselected and characterized for aminoglycoside mediated readthrough. Aclone with optimal growth characteristics and strong response (EC₅₀ of1.5 mM) to paromomycin was pursued for HTS assay development.Readthrough of Y122X accumulates an intracellular localized fusionprotein approximately 65.5 kDa in size as controlled by western blotanalysis and immunofluorescence using an anti-renilla antibody. The eGFPreporter pre-PTC mutation serves as visual control for genetic stabilityof the screening clones and minimizes protein degradation of smallfusion protein amounts. In the assay, compound concentration was 10 μM.In miniaturized 1536 well format 2000 cells were dispensed in 4 μl/welland incubated for 24 h at 37° C., 5% CO₂. 40 nl compounds were placed onthe cells with control wells containing 1 ul Paramomycin and 14.4 mMfinal concentration. Compounds were incubated for 24 h. Renilla Glosubstrate (2.5 ul) was added and plates were centrifuged and processedfor luminescence measurement using various readers. Activity calculationwas done using the equation: A1(%)=100*(S−NC)/(AC−NC) where AC, NC and Scorrespond to active controls (injection of Stimulation buffer=100%stimulation), neutral controls (buffer injection which Iloprost EC10)and screening samples (S). NC corresponds to 0% activity whereas AC is100% activity (14 mM paromomycin). False positive artefacts were removedin confirmation and validation screening using the same assay formatfollowed by counterscreening using the respective wildtype construct(w/o PTC mutation) cell model. Compounds were tested up to 100 μMcompound concentration.

TABLE 2 In-vitro activity in CFTR-Y122X assay: Table 2 represents AC₅₀values for nonsense mutation suppression in the CFTR-Y122X assay.A_(max) AC₅₀ Ex [%] [μM] 1.1 258 1.3 1.2  63 — 1.3 279 6.1 1.4 279 4.01.5 170 1.1 1.6 165 6.1 1.7  7 3.8 1.8  18 11.8 1.9 200 11.7 1.10 27711.0 1.11 188 9.1 1.12 391 4.8 1.13  13 — 1.14  18 — 1.15 169 7.8 1.16200 9.3 1.17 230 8.8 1.18 248 6.9 1.19   16^(b) — 1.20  65 13.8 1.21 16710.2 1.22  23 1.9 1.23 139 13.4 1.24 140 11.5 1.25  68 19.5 1.26 254 9.61.27 271 6.8 1.28 361 7.6 1.29 336 7.1 1.30 262 6.5 1.31 177 10.6 1.32 38 — 1.33  16 0.7 1.34  16 3.2 1.35  13 1.5 1.36  9 1.0 1.37 348 0.91.38  15 — 1.39 250 3.2 1.40 112 12.1 1.41 198 19.5 1.42 117 15.7 1.43 9 — 1.44 118 15.2 1.45 389 4.7 1.46  25 — 1.47 210 11.3 1.48 235 11.72.1 102 21.0 2.2 235 2.1 2.3 101 21.6 2.4 258 6.1 2.5 243 8.1 2.6^(a)127 — 2.7^(a) 151 — 2.8 264 10.6 2.9  73 18.4 2.10  25 25 2.11 192 10.72.12   23^(a) — 2.13  11 — 2.14  9 6.6 2.15 275 3.8 2.16 312 8.6 2.17293 5.8 2.18 222 9.9 2.19 248 11.6 2.20 201 2.3 2.21 214 7.6 2.22 19711.0 2.23 181 5.0 2.24 170 2.3 2.25 149 6.4 2.26  97 11.1 2.27   97^(a)— 2.28  89 15.1 2.29  73 14.3 2.30  71 22.2 2.31  67 2.5 2.32   43^(d) —2.33   18^(d) — 2.34  33 8.4 2.35  31 9.4 2.36  29 3.5 2.37   28^(d) —2.38  21 10.0 2.39   31^(e) — 2.40  20 6.7 2.41  18 4.9 2.42  18 10.72.43  17 14.7 2.44  16 — 2.45  14 11.0 2.46  12 4.2 2.47  10 3.1 2.48  7^(d) — 2.49  7 1.8 2.50  6 4.4 2.51   6^(a) — 3.1  65 5.8 3.2 29411.6 3.3  18 3.5 3.3  18 3.5 3.3  18 3.5 ^(a)% nonsense mutationsuppression relative to paromomycin reference activity; measured at 25μM compound concentration ^(b)% nonsense mutation suppression relativeto paromomycin reference activity; measured at 12.5 μM compoundconcentration ^(c)% nonsense mutation suppression relative toparomomycin reference activity; measured at 31 μM compound concentration^(d)% nonsense mutation suppression relative to paromomycin referenceactivity; measured at 100 μM compound concentration ^(e)% nonsensemutation suppression relative to paromomycin reference activity;measured at 50 μM compound concentration

The following compounds of formula (I) were tested in the abovedescribed CFTR-Y122X assay at the above dose ranges; suppressionreaching only less than 5% of paromomycin reference activity was seen:

-   2-isopropyl-10-methyl-3-phenyl-7-(trifluoromethyl)pyrimido[4,5-b]quinoline-4,5(3H,10H)-dione;-   3-cycloheptyl-2-(2-fluorophenyl)-10-methylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione;-   2-(4-chlorophenyl)-3-cyclopentyl-10-methylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione;-   3-cycloheptyl-10-methyl-2-(4-nitrophenyl)pyrimido[4,5-b]quinoline-4,5(3H,10H)-dione;-   3-cycloheptyl-2-(4-fluorophenyl)-10-methylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione;-   3-cycloheptyl-2-(2,4-dichlorophenyl)-10-methylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione;-   2-(4-chlorophenyl)-3-cycloheptyl-10-methylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione;-   2-(4-(tert-butyl)phenyl)-3-cycloheptyl-10-methylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione;-   2-(4-(tert-butyl)phenyl)-3-cyclohexyl-10-methylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione;-   3-cyclohexyl-2-(2,4-dichlorophenyl)-10-methylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione;-   3-cycloheptyl-2-cyclohexyl-10-methylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione;-   2,3-dicyclohexyl-10-methylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione;-   2-(4-(tert-butyl)phenyl)-3-cyclopentyl-10-methylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione;-   2-cyclohexyl-3-(3,5-dimethylphenyl)-10-methylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione;-   3-(3-chlorophenyl)-2-cyclohexyl-10-methylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione;-   10-isobutyl-2-isopropyl-3-phenylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione;-   2-isopropyl-10-methyl-3-(tetrahydrofuran-3-yl)pyrimido[4,5-b]quinoline-4,5(3H,10H)-dione;    and-   3-cyclopentyl-2-(1-cyclopentylpiperidin-3-yl)-10-methylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione.

1.2 In-Vitro Testing: Coagulation Factor 9-R29X Assay

Activity of compounds of the present invention was examined usingreporter constructs of full length human coagulation factor F9containing the R29X (TAG) mutation known from hemophilia B patients(“F9-R29X assay”). Full length F9 cDNA was stably expressed in the aboveisogenic HekR4 cell background. Stop codon readthrough and full lengthF9 expression was determined with a miniaturized confocal highthroughput imaging assay. In paraformaldehyde fixed and permeabilizedcells (10 uM compound; 24 h incubation) F9 expression was identifiedwith a commercial F9 antibody raised against the F9 C-terminus. Theantibody does not detect the truncated F9 protein (R29X) from solventcontrol treated cells. F9 staining intensity (Alexa-Fluor 488) and Draq5nuclear staining served as readout for data calculation. Percentactivity was measured in comparison to high (active control) and lowcontrols (DMSO solvent). A dose-response analysis for compound inducedF9 expression of the PTC mutant (R29X) was determined using a F9 ELISAassay.

TABLE 3 In-vitro activity in F9-R29X assay: Table 3 represents AC₅₀values for nonsense mutation suppression in the F9-R29X assay. A_(max)AC₅₀ Ex [%] [μM] 2.17 157 5.4 2.20 158 5.5 2.31 167 1.9

1.3 In-Vitro Testing: α-L-Iduronidase-Q70X/-W402X Assay

Activity of compounds of the present invention was examined using afunctional readout for two clinically common stop codon (TAG) mutants(Q70X, W402X) of the lysosomal enzyme α-L-iduronidase. Lack ofα-L-iduronidase expression in such stop codon patients leads to thelysosomal storage disorder Mucopolysaccharidosis I (MPSI) also calledHurler syndrome. Reporter constructs analogous to constructs above wereexpressed. In the assay, 2500 cells/well were treated for 48 h withcompound, washed with PBS and lysed (0.4 M Sodiumformate, 0.1% NaN3,0.9% NaCl, 0.2% Triton, pH 3.5). Restored α-L-iduronidase activity incell lysates was measured with the fluorescent 4-MU iduronide substrate(4 Methylumbelliferyl α-L-iduronide) after 45 min incubation. Again,paromomycin was used as reference control (14 mM).

TABLE 4 In-vitro activity in α-L-iduronidase -Q70X/-W402X assay: Table 3represents AC₅₀ values for nonsense mutation suppression in theα-L-iduronidase -Q70X/-W402X assay. Q70X Q70X W402X W402X Ex A_(max) [%]AC₅₀ [μM] A_(max) [%] AC₅₀ [μM] 2.17 265 2.1 211 2.9 2.20 386 1.0 1890.9 2.31 438 1.7 300 2.9

1-11. (canceled)
 12. A pharmaceutical composition comprising atherapeutically effective amount of a compound of formula (I) in freeform or in pharmaceutically acceptable salt form which is

wherein R₁ is a five- to six-membered monocyclic saturated orunsaturated non-aromatic ring system, wherein said ring system maycontain from 1 to 4 hetero atoms selected from nitrogen, oxygen andsulfur, and wherein said ring system may be substituted once or morethan once by R₆; and R₂ is C₂₋₆alkyl which may be substituted once ormore than once by R₇; or R₂ is —X₁—R₈; —X₁— is —O—, —S— or —N(R₉)—; R₉is hydrogen or C₁₋₄alkyl; and R₈ is C₁₋₆alkyl which may be substitutedonce or more than once by R₁₀; or R₂ is a three- to five-memberedmonocyclic saturated or unsaturated non-aromatic ring system, whereinsaid ring system may contain from 1 to 4 hetero atoms selected fromnitrogen, oxygen and sulfur, and wherein said ring system may besubstituted once or more than once by R₁₁; or R₁ is

wherein the phenyl ring is attached via the bond marked with anasterisk; each R₁₂ independently is hydrogen, halogen, hydroxyl, amino,cyano, nitro, C₁₋₄alkyl, C₁₋₄halogenalkyl, C₁₋₄hydroxyalkyl,C₁₋₄alkoxy-C₁₋₄alkyl, amino-C₁₋₄alkyl, C₁₋₄alkyl-amino-C₁₋₄alkyl,di(C₁₋₄alkyl)-amino-C₁₋₄alkyl, C₁₋₄alkoxy, C₁₋₄halogenalkoxy,C₁₋₄alkylamino or di(C₁₋₄ alkyl)amino; or C₃₋₆cycloalkyl, wherein onecarbon atom may be replaced by an oxygen atom, wherein theC₃₋₆cycloalkyl may be attached directly or via a C₁₋₂alkylene, andwherein the C₃₋₆cycloalkyl may be substituted once or more than once byhalogen; and R₂ is C₂₋₇alkyl which may be substituted once or more thanonce by R₁₃; or R₂ is —X₂—R₁₄; —X₂— is —O—, —S— or —N(R₁₅)—; R₁₅ ishydrogen or C₁₋₄alkyl; and R₁₄ is C₁₋₆alkyl which may be substitutedonce or more than once by R₁₆; or R₂ is a three- to five-memberedmonocyclic saturated or unsaturated non-aromatic ring system, whereinsaid ring system may contain from 1 to 4 hetero atoms selected fromnitrogen, oxygen and sulfur, and wherein said ring system may besubstituted once or more than once by R₁₇; R₃ is hydrogen or —CH₂R₁₈;R₁₈ is hydrogen, C₁₋₄alkyl, C₂₋₆alkenyl, C₃₋₆cycloalkyl,C₁₋₃alkoxyC₁₋₃alkyl, hydroxyC₁₋₃alkyl, or aminoC₁₋₃alkyl; and R₄ ishydrogen, halogen, hydroxyl, amino, cyano, C₁₋₄alkyl, C₁₋₄halogenalkyl,C₁₋₄ hydroxyalkyl, C₁₋₄alkoxy-C₁₋₄alkyl, amino-C₁₋₄alkyl,C₁₋₄alkyl-amino-C₁₋₄alkyl, di(C₁₋₄alkyl)-amino-C₁₋₄alkyl, C₁₋₄alkoxy,C₁₋₄halogenalkoxy, C₁₋₄alkylamino or di(C₁₋₄alkyl)amino; or a three- toseven-membered monocyclic aromatic, saturated or unsaturatednon-aromatic ring system, wherein said ring system may contain from 1 to4 hetero atoms selected from nitrogen, oxygen and sulfur, wherein saidring system may be attached directly or via a C₁₋₂ alkylene, and whereinsaid ring system may be substituted once or more than once by R₁₉; or R₃and R₄ taken together are —CH₂—CH₂—; R₅ is hydrogen, halogen, hydroxyl,cyano, C₁₋₄alkyl, C₂₋₄alkenyl, C₂₋₄alkinyl or C₁₋₄alkoxy; orC₃₋₄cycloalkyl, wherein one carbon atom may be replaced by an oxygenatom, wherein the C₃₋₄cycloalkyl may be attached directly or via aC₁₋₂alkylene; R₆, R₁₁, R₁₇ and R₁₉ each independently is halogen,hydroxyl, amino, cyano, nitro, C₁₋₄alkyl, C₁₋₄halogenalkyl,C₁₋₄hydroxyalkyl, C₁₋₄alkoxy-C₁₋₄alkyl, amino-C₁₋₄alkyl,C₁₋₄alkyl-amino-C₁₋₄ alkyl, di(C₁₋₄alkyl)-amino-C₁₋₄alkyl, C₁₋₄alkoxy,C₁₋₄halogenalkoxy, C₁₋₄alkylamino or di(C₁₋₄ alkyl)amino; orC₃₋₆cycloalkyl, wherein one carbon atom may be replaced by an oxygenatom, wherein the C₃₋₆cycloalkyl may be attached directly or via aC₁₋₂alkylene, and wherein the C₃₋₆cycloalkyl may be substituted once ormore than once by halogen; or two R₆, R₁₁, R₁₇ or R₁₉ at the same ringatom together are oxo; or two R₆, R₁₁, R₁₇ or R₁₉ at the same ringcarbon atom together with said carbon atom form a C₃₋₆cycloalkyl; R₇,R₁₀, R₁₃ and R₁₆ each independently is halogen, hydroxyl, amino, cyano,nitro, C₁₋₄alkoxy, C₁₋₄halogenalkoxy, C₁₋₄alkylamino ordi(C₁₋₄alkyl)amino; or C₃₋₆cycloalkyl, wherein one carbon atom may bereplaced by an oxygen atom, wherein the C₃₋₆cycloalkyl may be attacheddirectly or via a C₁₋₂alkylene, and wherein the C₃₋₆cycloalkyl may besubstituted once or more than once by halogen; or two R₇, R₁₀, R₁₃ orR₁₆ at the same carbon atom together are oxo; or two R₇, R₁₀, R₁₃ or R₁₆at the same carbon atom together with said carbon atom form aC₃₋₆cycloalkyl.
 13. A pharmaceutical composition according to claim 12wherein R₁ is

wherein the phenyl ring is attached via the bond marked with anasterisk; each R₁₂ independently is hydrogen, halogen, hydroxyl, amino,cyano, nitro, C₁₋₄alkyl, C₁₋₄halogenalkyl, C₁₋₄hydroxyalkyl,C₁₋₄alkoxy-C₁₋₄alkyl, amino-C₁₋₄alkyl, C₁₋₄alkyl-amino-C₁₋₄alkyl,di(C₁₋₄alkyl)-amino-C₁₋₄alkyl, C₁₋₄alkoxy, C₁₋₄halogenalkoxy,C₁₋₄alkylamino or di(C₁₋₄ alkyl)amino; or C₃₋₆cycloalkyl, wherein onecarbon atom may be replaced by an oxygen atom, wherein theC₃₋₆cycloalkyl may be attached directly or via a C₁₋₂alkylene, andwherein the C₃₋₆cycloalkyl may be substituted once or more than once byhalogen; and R₂ is C₂₋₇alkyl which may be substituted once or more thanonce by R₁₃; or R₂ is —X₂—R₁₄; —X₂— is —O—, —S— or —N(R₁₅)—; R₁₅ ishydrogen or C₁₋₄alkyl; and R₁₄ is C₁₋₆alkyl which may be substitutedonce or more than once by R₁₆; or R₂ is a three- to five-memberedmonocyclic saturated or unsaturated non-aromatic ring system, whereinsaid ring system may contain from 1 to 4 hetero atoms selected fromnitrogen, oxygen and sulfur, and wherein said ring system may besubstituted once or more than once by R₁₇; R₃ is hydrogen or —CH₂R₁₈;R₁₈ is hydrogen, C₁₋₄alkyl, C₂₋₆alkenyl, C₃₋₆cycloalkyl,C₁₋₃alkoxyC₁₋₃alkyl, hydroxyC₁₋₃alkyl, or aminoC₁₋₃alkyl; and R₄ ishydrogen, halogen, hydroxyl, amino, cyano, C₁₋₄alkyl, C₁₋₄halogenalkyl,C₁₋₄ hydroxyalkyl, C₁₋₄alkoxy-C₁₋₄alkyl, amino-C₁₋₄alkyl,C₁₋₄alkyl-amino-C₁₋₄alkyl, di(C₁₋₄alkyl)-amino-C₁₋₄alkyl, C₁₋₄alkoxy,C₁₋₄halogenalkoxy, C₁₋₄alkylamino or di(C₁₋₄alkyl)amino; or a three- toseven-membered monocyclic aromatic, saturated or unsaturatednon-aromatic ring system, wherein said ring system may contain from 1 to4 hetero atoms selected from nitrogen, oxygen and sulfur, wherein saidring system may be attached directly or via a C₁₋₂ alkylene, and whereinsaid ring system may be substituted once or more than once by R₁₉; or R₃and R₄ taken together are —CH₂—CH₂—; R₅ is hydrogen, halogen, hydroxyl,cyano, C₁₋₄alkyl, C₂₋₄alkenyl, C₂₋₄alkinyl or C₁₋₄alkoxy; orC₃₋₄cycloalkyl, wherein one carbon atom may be replaced by an oxygenatom, wherein the C₃₋₄cycloalkyl may be attached directly or via aC₁₋₂alkylene; R₁₃ and R₁₆ each independently is halogen, hydroxyl,amino, cyano, nitro, C₁₋₄alkoxy, C₁₋₄ halogenalkoxy, C₁₋₄alkylamino ordi(C₁₋₄alkyl)amino; or C₃₋₆cycloalkyl, wherein one carbon atom may bereplaced by an oxygen atom, wherein the C₃₋₆cycloalkyl may be attacheddirectly or via a C₁₋₂alkylene, and wherein the C₃₋₆cycloalkyl may besubstituted once or more than once by halogen; or two R₁₃ or R₁₆ at thesame carbon atom together are oxo; or two R₁₃ or R₁₆ at the same carbonatom together with said carbon atom form a C₃₋₆cycloalkyl; R₁₇ and R₁₉each independently is halogen, hydroxyl, amino, cyano, nitro, C₁₋₄alkyl,C₁₋₄ halogenalkyl, C₁₋₄hydroxyalkyl, C₁₋₄alkoxy-C₁₋₄alkyl,amino-C₁₋₄alkyl, C₁₋₄alkyl-amino-C₁₋₄ alkyl,di(C₁₋₄alkyl)-amino-C₁₋₄alkyl, C₁₋₄alkoxy, C₁₋₄halogenalkoxy,C₁₋₄alkylamino or di(C₁₋₄ alkyl)amino; or C₃₋₆cycloalkyl, wherein onecarbon atom may be replaced by an oxygen atom, wherein theC₃₋₆cycloalkyl may be attached directly or via a C₁₋₂alkylene, andwherein the C₃₋₆cycloalkyl may be substituted once or more than once byhalogen; or two R₁₇ or R₁₉ at the same ring atom together are oxo; ortwo R₁₇ or R₁₉ at the same ring carbon atom together with said carbonatom form a C₃₋₆cycloalkyl.
 14. A pharmaceutical composition accordingto claim 12 wherein the compound is selected from2-isopropyl-10-methyl-3-phenylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione;10-methyl-2-pentyl-3-phenylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione;10-methyl-3-phenyl-2-propylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione;2-ethyl-10-methyl-3-phenylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione;3-(3,5-dimethylphenyl)-2-ethyl-10-methylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione;3-(3,5-dimethylphenyl)-10-methyl-2-pentylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione;3-(3,5-dimethylphenyl)-2-isopropyl-10-methylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione;3-(3,5-dimethylphenyl)-10-methyl-2-propylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione;3-cyclopentyl-2-isopropyl-10-methylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione;3-cyclopentyl-10-methyl-2-pentylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione;3-cyclopentyl-10-methyl-2-propylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione;3-cyclohexyl-10-methyl-2-propylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione;3-cyclohexyl-2-isopropyl-10-methylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione;or3-cyclopentyl-2-ethyl-10-methylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione.15. A compound which is selected from the group consisting of2-cyclobutyl-10-methyl-3-phenylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione;10-allyl-2-isopropyl-3-phenylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione;2-isopropyl-3-phenylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione;10-allyl-2-cyclobutyl-3-phenylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione;2-cyclobutyl-3-phenylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione;10-methyl-2-(3-methylcyclobutyl)-3-phenylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione;2-(3,3-dimethylcyclobutyl)-10-methyl-3-phenylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione;2-(3-methoxycyclobutyl)-10-methyl-3-phenylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione;10-methyl-2-(pentan-3-yl)-3-phenylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione;2-cyclopentyl-10-methyl-3-phenylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione;2-cyclopropyl-10-methyl-3-phenylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione;2-butyl-10-methyl-3-phenylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione;2-(3-methoxypropyl)-10-methyl-3-phenylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione;2-(4-methoxybutyl)-10-methyl-3-phenylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione;3-(2-fluorophenyl)-2-isopropyl-10-methylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione;3-(2-chlorophenyl)-2-isopropyl-10-methylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione;3-(2,6-dichlorophenyl)-2-isopropyl-10-methylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione;2-isopropyl-10-methyl-3-(o-tolyl)pyrimido[4,5-b]quinoline-4,5(3H,10H)-dione;2-isopropyl-3-(2-methoxyphenyl)-10-methylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione;2-isopropyl-10-methyl-3-(2-(trifluoromethyl)phenyl)pyrimido[4,5-b]quinoline-4,5(3H,10H)-dione;3-(3-chlorophenyl)-2-isopropyl-10-methylpyrimido[4,5-b]quinoline-4,5(3H,10OH)-dione;2-isopropyl-3-(3-methoxyphenyl)-10-methylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione;7-fluoro-2-isopropyl-10-methyl-3-phenylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione;7-chloro-2-isopropyl-10-methyl-3-phenylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione;7-bromo-2-isopropyl-10-methyl-3-phenylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione;2-isopropyl-7,10-dimethyl-3-phenylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione;9-isopropyl-8-phenyl-1H-pyrimido[4,5-b]pyrrolo[3,2,1-ij]quinoline-6,7(2H,8H)-dione;10-allyl-3-cyclopentyl-2-isopropylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione;3-cyclopentyl-2-isopropylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione;3-cyclopentyl-10-ethyl-2-isopropylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione;2-(sec-butyl)-3-cyclopentyl-10-methylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione;3-cyclopentyl-2-isobutyl-10-methylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione;2-(tert-butyl)-3-cyclopentyl-10-methylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione;2-isopropyl-10-methyl-3-(tetrahydro-2H-pyran-4-yl)pyrimido[4,5-b]quinoline-4,5(3H,10H)-dione;2-isopropyl-10-methyl-3-(piperidin-1-yl)pyrimido[4,5-b]quinoline-4,5(3H,10H)-dione;3-cyclopentyl-2-isopropyl-9-methoxy-10-methylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione;3-cyclopentyl-2-isopropyl-7-methoxy-10-methylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione;7-chloro-3-cyclopentyl-2-isopropyl-10-methylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione;7-bromo-3-cyclopentyl-2-isopropyl-10-methylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione;3-cyclopentyl-7-ethynyl-2-isopropyl-10-methylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione;3-cyclopentyl-2-isopropyl-10-methyl-4,5-dioxo-3,4,5,10-tetrahydropyrimido[4,5-b]quinoline-7-carbonitrile;9-chloro-3-cyclopentyl-2-isopropyl-10-methylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione;2-(ethylthio)-3-phenylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione;2-(dimethylamino)-3-phenylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione;and2-(dimethylamino)-10-methyl-3-phenylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione;10-(2-aminoethyl)-2-cyclobutyl-3-phenylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione;2-isopropyl-3-(2-isopropylphenyl)-10-methylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione;2-cyclobutyl-10-(2-hydroxyethyl)-3-phenylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione;3-(2-bromophenyl)-2-isopropyl-10-methylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione;10-(2-aminoethyl)-2-isopropyl-3-phenylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione;10-(2-hydroxyethyl)-2-isopropyl-3-phenylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione;2-isopropyl-10-(2-methoxyethyl)-3-phenylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione;2-isopropyl-3-phenyl-10-propylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione;2-isopropyl-10-methyl-3-(tetrahydro-2H-pyran-3-yl)pyrimido[4,5-b]quinoline-4,5(3H,10H)-dione;2-cyclobutyl-3-(2,6-dichlorophenyl)-10-methylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione;2-hexyl-10-methyl-3-phenylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione;2-heptyl-10-methyl-3-phenylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione;or salts of these compounds.
 16. A combination comprising atherapeutically effective amount of the compound of formula (I) asdescribed in claim 15 in free form or in pharmaceutically acceptablesalt form and one or more therapeutically active agents.